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CD44 is an adhesion molecule involved in several biological functions and 
the primary receptor for hyaluronan (HA).   In cartilage, CD44 participates in the 
interplay between cells and the extracellular matrix to fine tune cellular responses 
to cytokines and growth factors.  CD44 thus can act as a mediator between 
individual chondrocytes and the extracellular matrix.  The extracellular domain of 
CD44 binds to the HA/proteoglycan rich extracellular matrix, while the 
intracellular domain interacts with receptors like Smad1 and with the actin 
cytoskeleton inside the cell.  Recently, we have demonstrated that chondrocyte 
CD44 is proteolytically cleaved from the cell surface by an endogenous, 
sequential, two step process. First, there is an initial extracellular cleavage of 
CD44 by a matrix metalloproteinase, which releases a soluble CD44 in the 
extracellular matrix, followed by a γ-secretase transmembrane cleavage, which 
releases an intracellular tail domain of CD44. 
 
The main focus of this study is to understand the effects of releasing a 
CD44 intracellular domain (ICD) that occurs via the action of the γ-secretase 
 cleavage, and how intracellular accumulation of such fragments might interfere 
with endogenous, intact, CD44 function.  The first aim evaluates whether 
intracellular accumulation of ICD fragments can affect CD44 ability to bind to HA 
and retain a pericellular coat by acting as a negative competitor.  Another aim 
was to explore the mechanisms responsible for any effects ICD over-expression 
might have on CD44 function.  Our data suggests that intracellular CD44-ICD 
over-expression exerts dominant-negative effects on full length native CD44 by 
competing with binding to the cytoskeleton via ankyrin-3.  This is the first study 
that looks at possible effects of releasing multiple ICD fragments via γ-secretase 
cleavage in chondrocytes and as such, will provide useful information on possible 
significance of CD44 fragmentation in cartilage during osteoarthritis. 
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 CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
 
Articular cartilage homeostasis is the result of an equilibrium between catabolic 
and anabolic factors.  CD44 participates in the interplay between cells and the 
extracellular matrix to fine tune cellular responses to cytokines and growth factors.  In 
articular cartilage, CD44 binds to hyaluronan (HA), the major unbranched 
glycosaminoglycan of the extracellular matrix, while inside the cell the conserved 
cytoplasmic tail of CD44 binds to the actin cytoskeleton. These interactions are vital for 
CD44 to act as a mediator between individual chondrocytes and the extracellular 
environment to maintain tissue homeostasis. 
 
It has been previously reported that CD44 undergoes a sequential proteolytic 
cleavage in many tissues and pathologies.  First, a membrane type I matrix 
metalloprotease (MT1-MMP) and/or an ADAM-like protease such as ADAM17 or 
ADAM10 cleaves the extracellular domain of CD44, releasing a soluble fragment 
(solCD44) outside the cell.  Sequentially, the transmembrane domain is cleaved by γ-
secretase, releasing an intracellular fragment (CD44-ICD) inside the cell.  Previous 
studies suggest that the released CD44-ICD goes directly to the nucleus and actives 
transcription of different genes (Okamoto et al. 2001), however, it is still unknown 
whether a fraction can remain in the cytoplasm, and if so, what is the biological 
significance. 
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Our laboratory recently demonstrated that CD44 proteolytic cleavage observed in 
our model system in vitro is similar to CD44 fragmentation present in osteoarthritic (OA) 
chondrocytes (Takahashi et al., 2010).  This study presented here addresses the 
biological consequences of having a cytoplasmic CD44-ICD, and further investigates 
the mechanisms of how CD44-ICD can interfere with the endogenous full-length CD44 
function. 
 
1. Osteoarthritis 
Osteoarthritis (OA) is the most common disease of the joints that limits mobility 
due to the degradation of articular cartilage in the affected joint.  Symptoms can vary 
from minimal pain to acute pain and stiffness, depending on the degree of cartilage 
degeneration and functional limitation.  It is the most common form of arthritis, and 
affects nearly 21 million Americans, most over the age of 45. With the increasing rate of 
obesity in the U.S., estimates suggest a doubling in prevalence from the year 2000 to 
2020 (Felson, 1998).  There are multiple risk factors that can lead to OA including 
genetic factors, constitutional factors such as gender (females are more prone to 
develop OA), race (higher percentage of African-Americans develop OA when 
compared to Caucasians), age, obesity, high bone density, and biomechanical risk 
factors such as joint injury, reduced muscle strength, joint laxity and joint malalignment 
(National Collaborating Centre for Chronic Conditions, 2008). 
 
Osteoarthritis is the result of both mechanical and biological effects that 
destabilize the normal coupling of degradation and synthesis of articular cartilage 
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chondrocytes and extracellular matrix (ECM) and subchondral bone (Kuettner, 1998).  
Gene expression and metabolism in osteoarthritic cartilage is characterized by 
increased cell proliferation, synthesis of fibrocartilage matrix and secretion of matrix 
metalloproteases (MMPs), and inflammatory cytokines such as IL1α and TNFα 
(Goldring, 2000; Holloway et al., 2004). Due to the lack of understanding of the 
underlying mechanism that produces an increased catabolic rate and a decreased 
anabolic rate that leads to cartilage degeneration, the most available treatments for OA 
are targeted towards reducing pain. As a result, OA remains one of the few chronic 
diseases of aging without an effective treatment (Felson, 2009). 
 
This study attempts to understand the underlying mechanism for articular 
cartilage degeneration by studying the interactions of hyaluronan (HA), one of the major 
components of articular cartilage extracellular matrix, and its cell surface receptor 
CD44.  Constant communication between extracellular matrix and chondrocytes through 
CD44/HA interactions is essential to maintain cartilage homeostasis, and disruption of 
this interaction leads to cartilage degradation.  One mechanism that may be 
detrimentally affecting CD44/HA interactions is the proteolytic cleavage of CD44. 
 
 
2. Articular cartilage 
Articular cartilage is the major load-bearing tissue of the synovial joint with very 
limited regenerative capacity. It is composed of chondrocytes, which account for less 
than 5% of the total tissue volume (Kuettner, 1994), but are the entities responsible for 
  4 
maintenance and secretion of the extracellular matrix.  As shown in Figure 1, cartilage 
can be sub-classified into several layers. From superficial to deep: the superficial layer 
contains resting chondrocytes; the zone of proliferation contains chondrocytes 
undergoing mitosis; the zone of hypertrophy contains swollen hypertrophic 
chondrocytes stacked on top of each other; and the zone of calcification contains dead 
calcified cartilage matrix.  Articular cartilage is characterized by lack of blood supply, 
innervation, lymphatics and cell-cell contact.  Each chondrocyte is surrounded by an 
extensive extracellular matrix and together, cells and matrix play an important role in 
communication to withstand the highly repetitive stresses that occur in the synovial joint 
(Blain, 2009).  Interactions between the cell and the extracellular matrix are vital to 
maintain cartilage homeostasis (Knudson and Knudson, 1993).  These interactions are 
mediated via cell surface receptors, which direct assembly and retention of the matrix 
and provide a linkage to the cytoskeleton and cytosolic components of signaling 
pathways (Knudson, 2003). 
 
2.1. The extracellular matrix of articular cartilage: 
Extracellular matrix in articular cartilage can be divided into a pericellular 
compartment, referring to ECM components directly associated with cell surface 
receptors along the cell membrane of each individual cell; the territorial compartment 
comprising the complex aura of ECM that forms around each cell; and the interterritorial 
compartment, which includes the less-dense ECM between territorial compartments of 
adjacent cells.  The extracellular matrix is composed of a complex collagen network, 
proteoglycans and non-collagenous glycoproteins; however, the major component is  
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A.       B. 
 
Figure 1:  Characteristic zones in articular cartilage.  A. The illustration shows the 
different morphology of chondrocytes among individual zones.  B.  Histological sample 
of bovine articular cartilage stained with safranin O and fast green counter-stain 
showing the three morphological zones.  The red dye from the safranin O reflects the 
rich proteoglycan content of the articular cartilage. 
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water, which accounts for roughly 70% of the total tissue volume (Kuettner, 1994).  
Large water volume provides cushioning for the mechanical pressures produced in the 
joints, protecting the articular cartilage of adjacent bones. 
 
The interwoven collagen fibers represent about 50% of the organic dry weight in 
articular cartilage, and provide a network that gives tensile strength and support to the 
tissue, and the capacity to contain the swelling pressure of the embedded aggrecan 
proteoglycan (Knudson and Knudson, 1993).  In adult cartilage, about 90% of the total 
collagens are type II collagen, a type found only in a few other tissues.  Chondrocytes 
are responsible for collagen synthesis in articular cartilage, and changes in collagen 
expression have been associated with OA cartilage (Kuettner, 1994). 
 
 Proteoglycans play an important role in regulating osmotic pressure in the 
synovial joint.  The negative charge of proteoglycans interacts with water molecules 
allowing the tissue to undergo reversible deformation during mechanical pressure.  
Aggrecan is the most abundant proteoglycan in articular cartilage, accounting for about 
90% of the mass of proteoglycans in the tissue (Kuettner, 1994).  The globular G1 core 
protein domain of aggrecan binds to hyaluronan directly—a binding that is further 
stabilized by a link protein to form a proteoglycan aggregate (Figure 2).  Hyaluronan is a 
high molecular weight glycosaminoglycan composed of repeating disaccharides of 
glucuronic acid and N-acetylglucosamine.  The nonbranching linear hyaluronan 
macromolecule and acts as the core filament for aggrecan aggregates (Knudson, 1993).   
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Figure 2: The extracellular matrix of chondrocytes.  Figure depicts the interaction 
between a normal articular chondrocyte with its adjacent extracellular matrix.   Several 
components of the cartilage / chondrocyte extracellular matrix are highlighted including 
the cartilage-specific collagens, various proteoglycans present in cartilage and HA.   Of 
particular interest to this study, the model depicts how HA is synthesized at the plasma 
membrane via HA synthases (HAS), as well as the retention of HA by the cell surface 
receptor CD44.  Also highlighted is the binding of the globular G1 domain of aggrecan 
to HA, that together with bound link proteins, forms the cartilage proteoglycan aggregate 
(modified from Knudson and Knudson 2005). 
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Hyaluronan is synthesized directly at the cell membrane of chondrocytes by a 
membrane hyaluronan synthase complex termed HAS (Figure 2).   In chondrocytes, 
HAS-2 is the primary enzyme (Nishida et al., 1999) and newly-synthesized hyaluronan 
is released directly into the extracellular matrix after termination of chain elongation.  
Once released hyaluronan interacts with the cells via cell membrane receptors such as 
CD44 (Knudson, 1993; Knudson, 1996). It has been shown that hyaluronan is critical to 
maintain the structure of the extracellular matrix, and it also affects adhesion, migration 
and differentiation of embryonic chondrocytes in early limb formation (Knudson and 
Toole, 1985; Knudson and Toole, 1987; Maleski and Knudson, 1996). CD44 interacts 
with the extracellular environment by binding to hyaluronan, while inside the cell the 
intracellular domain binds to different elements of the cytoskeleton and cytosolic 
proteins via the intracellular domain to activate different signaling pathways. 
 
2.2. Cytoskeletal components in articular chondrocytes: 
 The chondrocyte cytoskeleton plays a major role in maintaining the chondrocyte 
phenotype (Benya et al., 1988; Benya and Shaffer, 1982; Nofal and Knudson, 2002) 
and activating signaling pathways in response to mechanical stimuli or changes in the 
composition of the extracellular matrix—events mediated by matrix receptors.  The 
cytoskeleton is composed of actin microfilaments, tubulin microtubules and intermediate 
filaments.  The actin microfilaments contribute to changes in cell shape, movement of 
organelles, cell adhesion and migration, endocytosis, secretion, and extracellular matrix 
formation.   Microtubules contribute to organelle trafficking, cell motility and division, and 
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cell morphogenesis and organization.  The less studied vimentin intermediate filaments 
are believed to be involved in signal transduction (Blain, 2009). 
 
In normal articular cartilage (non-OA), the three dimensional cytoskeleton of 
chondrocytes is cortical in the middle and deep zone cells, as well as in the more 
flattened disc-shaped cells that are present in the superficial zone (Figure 1).  However, 
morphological changes are often observed in osteoarthritic cartilage, in which the 
chondrocytes develop a complex fibrous structure extending from the cytoplasm in all 
directions (Holloway et al., 2004).These elongated processes are more prominent in the 
superficial and middle zone of OA cartilage, but it is still unknown whether these cells 
contribute directly to the breakdown of cartilage tissue through the release of catabolic 
agents from the cell processes, or whether the processes are a result of matrix 
degradation (Holloway et al., 2004). 
 
3. Structure and function of CD44 
 CD44 is a type I transmembrane protein found in the cell surface of many 
tissues, including articular cartilage and plays a critical role in a diversity of cell 
behaviors including cell adhesion, migration, invasion and survival (Cichy and Pure, 
2003) as well as pericellular matrix assembly (Knudson, 1993).  In humans, it is 
encoded by a single gene located in chromosome 11p13 and comprises at least 20 
exons (Martin et al., 2003). CD44 is synthesized as a small 37 kD protein, but due to 
alternative splicing of the variable exon region and post-translational modifications such 
as variable N- and O-linked glycosylation, the molecular size varies between 80-200 kD 
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(Marhaba and Zoller, 2004).  The standard isoform (CD44s) also known as the 
hematopoietic isoform of CD44 (CD44H) comprise exons 1-5, 16-18 and 20, and is 
composed of 341 amino acids (Martin et al., 2003). Once localized in the plasma 
membrane, the N-terminal of CD44 is oriented as the extracellular domain, followed by 
a transmembrane domain and C-terminal cytoplasmic domain (Figure 3). 
 
 The extracellular domain of CD44H is composed of 248 amino acids, and can be 
subdivided into two regions; membrane proximal and membrane distal.  The membrane 
distal N-terminal region is encoded by exons 1-5 and is highly conserved (85%) in 
mammalian species.   The membrane distal region contains the so-called “link-
homology domain” due to its homology to HA binding regions present on link proteins 
and aggrecan. The link-homology domain is stabilized by three pairs of disulfide bonds 
and is responsible for binding ligands present within the extracellular matrix (Martin et 
al., 2003).  The principal ligand for CD44 is HA, but other extracellular macromolecules 
have also been reported to bind including type I collagen, fibronectin, fibrin, laminin and 
chondroitin sulfate (Naor et al., 1997).  Binding of CD44 to hyaluronan has multiple 
effects on cell proliferation, motility and survival of both malignant and nonmalignant 
cells (Anderegg et al., 2009).   
 
The less conserved (35-50%) membrane proximal region is encoded by exons 
16-17 and in part by exon 5 (Martin et al., 2003).  This domain is responsible for 
different CD44 isoforms by expressing post-translational glycosylation and alternative  
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A. 
B. 
Figure 3: CD44 structure.  A. CD44 is composed of an extracellular, transmembrane 
and intracellular domain.  The extracellular domain contains the binding motif to HA, as 
well as a variable region in which different CD44 isoforms can be generated via 
alternative splicing of variant exons.  The cytoplasmic tail contains putative ERM and 
ankyrin binding domains that interact with the actin cytoskeleton. B. CD44 sequence 
showing the extracellular domain (blue) containing the HA binding site (pink) and three 
predicted MMP cleavage sites, the transmembrane domain (green) with two γ-
secretase sites, and the intracellular domain with an ERM and ankyrin binding domains 
(orange). 
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splicing (of exons 6-15).  This short stalk region at the end of the link domain connects 
the extracellular domain with the transmembrane domain. 
 
 The short transmembrane domain is composed of 23 hydrophobic amino acids 
and a cysteine residue (cys286) encoded by exon 18.  It has been suggested that the 
transmembrane domain may be involved in CD44 oligomerization and transport of the 
protein into lipid rafts (Marhaba and Zoller, 2004; Thankamony and Knudson, 2006).  
Thankamony and Knudson found that mutation of cys286 to ala286 or ser286 had no effect 
on HA binding but prevented the movement of CD44 into lipid rafts and prevented 
CD44-mediated endocytosis of HA. 
 
The highly conserved (80-90%) intracellular domain is encoded in part by exon 
18 and all of exon 20 (Martin et al., 2003).  It is composed of 72 amino acids and is 
thought to be important in regulating the functions of CD44 including HA binding, HA 
endocytosis, signal transduction and cell migration.  The CD44 intracellular domain has 
no intrinsic kinase activity, thus signal transduction is likely mediated through 
interactions with the cytoskeleton via an ERM (ezrin/radixin/moesin) and ankyrin binding 
domains (Knudson and Peterson, 2004).  The ERM binding domain of CD44 includes 
amino acids 292-300, which is located between the transmembrane domain and the 
intracellular membrane-proximal domain.  Distal to the ERM binding domain is the 
ankyrin binding motif including amino acids 304-318 (Marhaba and Zoller, 2004).  
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Studies have shown that disruption of the actin cytoskeleton using cytochalasin D 
disrupts CD44/HA interactions and decreased matrix retention (Lesley et al., 1992; Liu 
et al., 1996; Nofal and Knudson, 2002).  In addition, over-expressing a negative 
competitor to the CD44/ankyrin binding motif blocked HA-mediated Ca2+ signaling in 
endothelial cells (Singleton and Bourguignon, 2004).  Therefore, binding of CD44 
cytoplasmic tail to the cytoskeleton is essential for CD44 ability to retain a pericellular 
coat and mediate outside-in signaling. 
 
It is still unclear whether CD44 can interact with both ERM and ankyrin 
simultaneously forming a single complex, or whether CD44/ERM and CD44/ankyrin are 
two separate mutually exclusive complexes that are utilized in a tissue dependent 
manner.    To date, there is only indirect evidence to suggest that CD44 interacts with 
cytoskeletal proteins in articular chondrocytes (Nofal and Knudson, 2002).  A direct 
interaction between the cytoplasmic tail of CD44 and cytoskeleton adaptor proteins has 
not been shown. 
 
3.1. CD44/ERM interactions: 
A crystal structure analysis of the FERM/CD44 complex revealed that the CD44 
ERM binding region contains a cluster of basic amino acids, Lys-Lys-Lys, followed by a 
nonpolar region (Figure 3B) which binds to the groove formed between helix α1C and 
the β-strand 5 of subdomain C (β5C) of the FERM domain (Mori et al., 2008). A 
functional analysis of the ezrin binding site in CD44 found that deletion of residues 289-
295 or 296-300 completely abolished association with ezrin, and that phosphorylation of 
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CD44 at Ser325 does not regulate ezrin binding.  Interestingly, the CD44 ERM binding 
domain mutants did not affect HA binding, suggesting that HA binding to CD44 is not 
dependent upon intracellular binding of CD44 to these cytoskeleton adaptor proteins 
(Legg and Isacke, 1998).  Based on these results, the proposed mechanism for 
CD44/ERM interactions suggest that ERM proteins do not have an inside-out effect on 
transmembrane receptor signaling, but rather regulate outside-in signaling events. 
Contrary to previous reports that CD44 and ERM play an important role in localization of 
the other (Hirao et al., 1996), ezrin mutants did not affect CD44 localization to the 
plasma membrane (Legg and Isacke, 1998).  
 
 ERM proteins exist in two states; an active state involved in protein-protein 
interactions, and a dormant state present in the cytoplasm. During the dormant state, 
the amino-terminal N-ERMAD (N-ERM Associated Domain) interacts with the carboxyl-
terminal C-ERMAD (C-ERM Associated Domain), changing the conformation of the 
protein and masking the binding sites for both the cytoskeletal and binding partners 
(Louvet-Vallee, 2000). ERM proteins can be activated by phosphorylation of 
serine/threonine residues by protein kinase C (moesin) and Rho kinase (ezrin/radixin).  
This phosphorylation disrupts the interaction between N-ERMAD and C-ERMAD, 
unmasking the binding sites for actin and ERM binding proteins (Matsui et al., 1998). 
Another suggested mechanism for ERM activation is by binding to 
phosphotidylinositides. In vitro studies have shown that addition of phosphatidylinositol 
phosphate (PIP) and phosphatidylinositol-4, 5 bisphosphate (PIP2) to the media is 
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necessary to detect CD44/ERM interactions (Hirao et al., 1996a) an observation that 
was later confirmed by in vivo studies (Matsui et al., 1999).  
 
 ERM proteins can also be switched to the dormant state.  One proposed 
mechanism for inactivation of ERM proteins is dephosphorylation of activated ERM, 
which changes the conformation of the protein and disrupts its interaction with the cell 
membrane and the cytoskeleton.  In myeloid cells, treatment with actin or kinase 
inhibitors disrupted CD44/ERM interactions and reduced HA binding (Brown et al., 
2005).  Another study looking at the effects of hyaluronidase-2 (Hyal2) over-expression 
in v-src-transformed rat fibroblasts (BB16 cells), found that parental cells had higher 
levels of pERM and cell motility when compared to their Hyal2 transfectants.  Hyal2 
interacts with CD44 disrupting binding to HA, which in turn disrupts CD44/ERM binding 
and ERM phosphorylation (Duterme et al., 2009). 
 
 In summary, it has been shown that ERM proteins act as cross-linkers or 
adapters between transmembrane proteins (CD44, ICAM-1,-2 and CD43) and the actin 
cytoskeleton in different tissues.  However, although it has been suggested that CD44 
interacts with the actin cytoskeleton in articular chondrocytes, there are no reports on 
the mechanism for this interaction such as interactions between CD44 and ERM 
proteins.    This lack of detectable ERM/CD44 binding may be due to predicted 
dissociation of CD44/ERM complexes under low ionic strength conditions (Tsukita and 
Yonemura, 1997).  It has been reported that, in fact, CD44/ERM interactions cannot be 
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detected in vitro or in vivo under physiological conditions, and activation of Rho or 
protein kinase C seems to be a requirement to activate binding. 
 
3.2. CD44/Ankyrin interactions: 
 Ankyrin is another family of adaptor proteins known to act as cross-linkers 
between cell surface receptors and cytoskeletal components.  In mammals, ankyrins 
are encoded by three different genes (ANK1, ANK2, ANK3) and each gene produces 
many different isoforms through alternative splicing.  At first, ankyrin was believed to act 
as a cross-linker between band 3 membrane protein to the cytoskeleton in erythrocytes, 
but now it is known to be highly expressed in different tissues and to interact with 
diverse membrane proteins (Bourguignon et al., 1998).  ANK1 (ankyrin R), also known 
as erythrocyte ankyrin, is located on chromosome 8 in both humans and mice.  It is 
highly expressed in erythrocytes, purkinje cells, and motor neurons in the spinal column 
and in the hippocampus.  ANK2 (ankyrin B), also known as the brain ankyrin, is the 
predominant ankyrin in the nervous system. It is encoded by a gene in human 
chromosome 4q and mouse chromosome 3 (Peters et al., 1995). ANK3 (Ankyrin G) was 
the last member of the ankyrin family to be described, but interestingly, ANK3 is the 
most abundant and diverse of the ankyrin family.  ANK3 can be found in kidney, most 
epithelial tissues, macrophages as well as cardiac, smooth and skeletal muscle tissues 
(Peters et al., 1995).  
 
 All ankyrins have three conserved domains: the N-terminal ankyrin-repeat 
domain (ARD) which consists of 33 amino acids, a spectrin binding domain and a C-
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terminal regulatory domain (Singleton and Bourguignon, 2004).   CD44 as well as other 
ankyrin binding partners, bind to the ARD through a conserved ankyrin binding domain 
within the cytoplasmic tail of CD44 (figure 3B).   Biochemical studies and in vitro 
mutagenesis of the ankyrin binding domain indicate that CD44/ankyrin interactions are 
required for both “outside-in” and “inside-out” cell activation events.  In addition, ankyrin 
binding domain of CD44 shares a large degree of sequence homology with the ankyrin 
binding domains of two Ca2+ channel proteins (the inositol triphosphate receptor, IP3R 
and ryanodine receptor).  This homology suggests an important role for ankyrin in 
CD44/ankyrin interactions necessary for HA binding, but also interactions necessary to 
regulate Ca2+ influx and subcellular localization of IP3Rs (Bourguignon et al., 1998).  
 
 Cytoskeletal proteins such as filamin, anexin II, ezrin, myosin and RhoA are 
known to localize within specialized plasma microdomains that contain lipid components 
such as cholesterol and sphingolipids, also known as lipid rafts.  This localization 
implies that cholesterol rich microdomains are involved in a variety of cellular functions 
related to cytoskeleton-receptor interactions.    As discussed above, a fraction of the 
total cell surface CD44 also localizes within lipid rafts, namely the fraction of CD44 that 
becomes palmitoylated at Cys286 and possibly Cys295 (Thankamony and Knudson, 
2006). A study in aortic endothelial cells (GM7372A) showed that the CD44 isoform 
expressed in these cells (CD44v10), interacts with two other proteins when present 
within lipid rafts; CD44v10 interacts with ankyrin and IP3R via the ARD domain of 
ankyrin.   This raft-dependent sorting and interaction plays an important role in 
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regulating Ca2+ signaling mediated by CD44/HA binding.    In the absence of HA, the 
CD44v10-ankyrin- IP3R complex failed to form and associate into the lipid rafts.   
 
In addition, disruption of the lipid rafts using methyl-β-cyclodextrin or interference 
of CD44/ankyrin binding by over-expressing ankyrin’s ARD fragments (these fragments 
act as competitive inhibitors), not only prevented ankyrin- IP3R receptor accumulation in 
lipid rafts, but also blocks HA-mediated Ca2+ signaling in endothelial cell functions 
(Singleton and Bourguignon, 2004).  
 
 Taken all together, CD44 has been demonstrated to bind to the cytoskeleton via 
ERM or ankyrin adaptor binding proteins, both of which act as cross-linkers between 
cell receptors and actin.   However, in vitro binding assays demonstrated that the 
binding affinity for CD44 and ankyrin interactions is much higher than that of CD44 and 
ERM (Lokeshwar et al., 1994; Tsukita and Yonemura, 1997).  To date, there are no 
reports of which adaptor protein functions as the intermediate in the linkage between 
CD44 and the actin cytoskeleton in articular chondrocytes.   In the study by Singleton 
and Bourguignon, they used ARD fragments of ankyrin to determine the mechanism of 
CD44 / ankyrin / IP3R interactions (Singleton and Bourguignon, 2004). In our study, 
over-expression of a CD44-ICD fragment will be used in a similar way to probe for 
CD44-FL and cytoskeleton adaptor protein interactions.  Additionally, intracellular 
competitive binding between the CD44-ICD and the cytoskeleton complexes may also 
affect CD44 functions that are dependent on cytoskeleton interactions. 
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3.3. Proteolytic cleavage of CD44: 
 Proteolytic cleavage of cell surface receptors is a key mechanism in cell 
migration and tumor metastasis.  During cell migration, cells rely on a highly polarized 
cell morphology.  When cell surface receptors bind to the ECM, actin polymerization 
creates protrusions of the leading edge.  Degradation of adhesion structures and of 
ECM by metalloproteinases allow the cell to advance forward by releasing matrix steric 
resistance at the leading edge, and detachment of the trailing edge by processes such 
as disassembly of adhesion structures and proteolytic cleavage of cell surface receptors 
(Marrero-Diaz et al., 2009).  
 
There is substantial evidence that CD44 undergoes a sequential proteolytic 
cleavage in a variety of cell types and tissues (Cichy and Pure, 2003; Lammich et al., 
2002; Murakami et al., 2003; Okamoto et al., 2001; Okamoto et al., 1999; Pelletier et al., 
2006).  Similar to Notch and Amyloid Precursor Protein, CD44 is cleaved in the 
extracellular domain releasing a soluble peptide (solCD44) followed by a cleavage in 
the transmembrane domain, which releases an intracellular fragment (CD44-ICD) 
(Figure 4). 
 
In the case of Notch, ligand binding to its receptors Delta and Jagged induces an 
extracellular proteolytic cleavage by ADAM metalloproteases, which is followed by a 
transmembrane domain cleavage by γ-secretase enzyme, releasing a Notch 
intracellular domain (ICD) inside the cell that translocates to the nucleus and promotes 
transcription.  This signaling pathway occurs during several developmental and  
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Figure 4: Sequential proteolytic cleavage of CD44 by a metalloproteinase and 
γ-secretase. Full length CD44 (CD44-FL) can be detected on a western blot with 
an antibody specific to the extracellular domain (BU52) or with CD44-cytotail 
antibody as an ~85 kD. After CD44 undergoes the first proteolytic cleavage by a 
metalloproteinase such as MT1-MMP or ADAM 10/17, the CD44-EXT fragment 
produced can be detected on a western blot with the CD44-cytotail antibody as a 
~15-20 kD.  Lastly, after γ-secretase cleavage, the CD44-ICD can be detected with 
the CD44-cytotail antibody as a ~15 kD by western blotting. 
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physiological processes, and Notch mutations have been associated with several 
pathologies such as T-cell acute lymphoblastic leukemia (Bray, 2006).  
 
This sequential proteolytic cleavage of CD44 may play a role in several 
pathological conditions. High levels of solCD44 have been detected in the serum of 
patients with different types of malignant cancer and metastasis (Guo et al., 1994; 
Masson et al., 1999; Yamane et al., 1999), arthritic synovial fluid (Haynes et al., 1991a), 
and cell culture media (Nakamura et al., 2004; Okamoto et al., 1999b), and has been 
associated with unfavorable outcomes in non-Hodgkin’s lymphoma (Nagano and Saya, 
2004) and resistance to chemotherapy in breast cancer patients (Kopp et al., 2001). In 
addition, solCD44 is used as a marker for breast cancer (Lackner et al., 1998), gastric 
and colon cancer (Guo et al., 1994), colorectal cancer (Masson et al., 1999), cervical 
cancer (Kainz et al., 1995), and non-Hodgkin lymphoma (Lockhart et al., 1999). 
Recently, our laboratory found that CD44 expression in OA chondrocytes resembles the 
pattern shown of CD44 proteolytic cleavage in different tissues (Takeda et al., 2010).  
 
Due to the important cell-cell and cell-matrix interaction properties of CD44, 
cancer biologists have shown an increased interest in CD44 shedding and over-
expression as an important mechanism for cancer metastasis and migration (Kajita et 
al., 2001). As a result, proteolytic cleavage of CD44 is a major area of research interest 
in cancer biology and other fields, but the processes that regulate this cleavage as well 
as the consequences, remain elusive. 
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3.3.1 The release of soluble CD44 
The first step of the sequential proteolytic processing of CD44 is an extracellular 
cleavage, which releases a soluble fragment (solCD44).  This cleavage is regulated by 
multiple signaling pathways including activation of PKC, the influx of extracellular Ca2+, 
members of the Rho family of small GTPases, and the Ras oncoprotein (Okamoto et al., 
1999). There are three different sites on the extracellular domain of CD44 that can get 
cleaved, possibly by different enzymes and mechanism (Figure 3B). 
 
Matrix metalloproteinase (MMPs) are a family of enzymes known to degrade the 
ECM.  A sub-group of this family known as membrane-type metalloproteinases (MT-
MMPs) are bound to the plasma membrane either through a transmembrane domain 
(Cao et al., 1995; Sato et al., 1994) or a glycosylphosphatidylinositol anchor (Kojima et 
al., 2000). MT1-MMP is the major membrane-type MMP expressed in tumor cells, and it 
appears to have an important role in cell migration and metastasis (Nakamura et al., 
1999; Ueno et al., 1997).    Interestingly, CD44 over-expression is also common in 
different types of cancer, and believed to be involved in cancer migration.  Both MT1-
MMP and CD44 were found to co-localize in the lamellipodia of migrating cells, and 
expression of MT1-MMP leads to an increase in CD44 shedding both in vitro (Kajita et 
al., 2001) and in vivo (Marrero-Diaz et al., 2009). A mutant form of CD44 that cannot be 
processed by MT1-MMP did not stimulate migration, suggesting that co-expression of 
MT1-MMP and CD44 is a possible mechanism involved in cell migration in which MT1-
MMP cleaves the extracellular domain of CD44, allowing the cells to move forward 
(Kajita et al., 2001).   
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Another study further identified the cleavage sites of the CD44 extracellular 
domain (Nakamura et al., 2004).  Nakamura and colleagues recognized three different 
sites (CS1, CS2, CS3, figure 3B) that generate three different solCD44 fragments (37-
40 kD, 50-60 kD, 65-70 kD respectively).  Furthermore, cleavage sites CS1 and CS2 
were inhibited using an MMP specific inhibitor (TIMP-2) but not by TIMP-1, which 
inhibits soluble MMPs but not MT-MMPs or ADAMs; therefore, these two sites were 
recognized as MT1-MMP targeted sites. Cleavage site CS3 was inhibited by TIMP3, a 
general inhibitor of all MMPs and ADAMs, but not by TIMP-1 and TIMP-2, suggesting 
that the enzyme responsible for that cleavage site belong to the ADAM family 
(Nakamura et al., 2004).  
 
ADAMs (A Disintegrin and A Metalloprotease domain) is a family of multidomain 
and multifunctional cell surface proteases that are related to MMPs.  From N to C 
terminus, all ADAMs contain a pro, metalloprotease, disintegrin, cystine-rich, spacer, 
transmembrane and cytoplasmic tail domains (White, 2005). They play a key role in 
initiating activation of key signaling pathways and regulating interactions between tumor 
cells and their microenvironment (Stamenkovic and Yu, 2009). It has been suggested 
that ADAM-10 and ADAM-17 are also involved in cleavage of the extracellular domain 
of CD44 (Murai et al., 2006; Nagano and Saya, 2004; Nakamura et al., 2004; 
Stamenkovic and Yu, 2009).  
 
Although the mechanism by which the CD44 extracellular domain is cleaved is 
still unclear, this step is a requirement for the second cleavage that occurs in the 
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transmembrane domain.  In a study, metalloprotease inhibitors successfully blocked all 
CD44 shedding, including the intracellular fragments, which are a result of presenilin-
dependent γ-secretase enzyme.  Inhibitors specific to γ-secretase still cleaved the 
extracellular domain of CD44, but blocked the shedding of the intracellular domain 
(Okamoto et al., 2001).  
 
3.3.2 The release of CD44 intracellular domain 
 
The second step in the sequential proteolytic shedding of CD44 includes a 
transmembrane cleavage by the presenilin-dependent γ-secretase enzyme. γ-secretase 
is a protease that cleaves bitopic membrane proteins within the lipid bilayer.  This 
enzyme also requires multiple components for enzymatic activity both in vivo and in 
vitro (Beel and Sanders, 2008). Presenilins are polytopic membrane proteins that are 
major constituents of the γ-secretase mediated transmembrane cleavage (Esler and 
Wolfe, 2001; Strooper and Annaert, 2001). In the case of CD44 transmembrane 
proteolysis, presenilin-1 was directly associated with the γ-secretase activity that 
releases the CD44 intracellular fragment (Murakami et al., 2003). Other substrates of γ-
secretase activity include Notch and Amyloid Precursor Protein. 
 
The target cleavage site within the transmembrane domain of CD44 occurs C-
terminal to Ala280 or Ile287, releasing a short peptide outside the cell, and the CD44 
intracellular domain (CD44-ICD) (Figure 4).   Some studies suggest that the released 
CD44-ICD translocates to the nucleus and promotes transcription through the TPA-
responsive element and activates gene expression, including CD44 itself (Okamoto et 
  25 
al., 2001). In addition, CD44-ICD has been proposed to be involved in early events of 
tumorigenesis and cancer metastasis by directly activating signaling pathways (Pelletier 
et al., 2006).  
 
Although nuclear translocation of the released CD44-ICD may occur, many 
questions still remain unanswered in regards to other possible roles of the released 
cytoplasmic CD44-ICD, including possible effects on endogenous CD44 and its 
cytoskeletal interactions.   We propose that the CD44-ICD, like the ectodomain, would 
act as an intracellular competitor to the interaction between endogenous full-length 
CD44 and cytoskeletal binding proteins. 
 
 
 
 
 
 
 
 
 
  
CHAPTER 2: MATERIALS AND METHODS 
 
1. Engineering expression plasmid constructs and fusion proteins. 
To study the effects of CD44-ICD over-expression on endogenous full-length CD44 
function, several expression plasmids containing full-length CD44H (CD44-FL), CD44-
ICD and Smad1 were prepared and characterized.  Some of these expression plasmids 
provided for the establishment of epitope-tag fusion proteins.  As seen in figure 5, 
different tags were used including C-terminal Myc, C-terminal EGFP (Enhanced Green 
Fluorescent Protein) or, N-terminal GFP (Green Fluorescent Protein).    For the CD44-
ICD, the Ala288 was chosen as the upstream start site because the Ile287 - Ala288 site 
within the transmembrane domain represents a major site for γ-secretase cleavage of 
CD44 (Okamoto et al., 1997). All of the CD44-ICD constructs were generated by PCR-
mediated amplification of CD44-FL, already cloned into a pCDM8 vector and 
characterized for expression and function (Jiang et al., 2002). 
 
1.1. Cloning strategies: 
1.1.1 Generation of CD44-ICD-myc and untaggedCD44-ICD 
A two-step cloning approach was used to generate an expression plasmid 
containing a CD44-ICD-myc or an untagged CD44-ICD insert (Figure 6).  Primer design 
required careful engineering to incorporate restriction sites that can be used for 
directional cloning into the pCMV/myc/cyto vector (Invitrogen, Carlsbad, CA).  The  
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Figure 5:  Summary of all fusion proteins.  All constructs engineered during this 
study are shown, including location of the epitope tag (N- terminal vs. C-terminal) and 
size of the insert, the epitope tag and the estimated size of the fusion protein. 
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Double digest with 
Sal I and Not I 
Figure 6:  Cloning strategy to generate an untagged CD44-ICD and a CD44-ICD-
myc.  A. PCR product amplified using primers with engineered Sal I and Not I sites was 
subcloned into a TOPO vector.  B.  A sequential double restriction digest using Sal I and 
Not I restriction enzymes removed the CD44-ICD from the TOPO vector, and the insert 
was then subcloned into the final pCMV/myc/cyto vector to create an untagged CD44-
ICD (primers included a stop codon) and a CD44-ICD-myc (primers omitted the stop 
codon). 
B. 
A. 
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pCMV/myc/cyto vector was chosen because it provides a start (ATG) site in the multiple 
cloning site (MCS) and a Kozak consensus sequence to facilitate expression of the 
protein.   In order to use this start site, primers were carefully designed to be in-frame 
with the ATG site. 
 
Both myc-tagged and untagged constructs were generated using the same 
upstream primer with an engineered Sal I site on the 5ʹ′ end: 5ʹ′GTCGACGCAGTCAAV 
AGTCGAAGAAGGTGTGG3ʹ′.  Primers were designed and generated using Integrated 
DNA Technologies (Coralville, IA) website.  The downstream primer for both constructs 
included an engineered Not I site at the 3’.  However, the untagged CD44-ICD included 
a stop codon (UAA) at the end of the sequence designed to generate the more native 
15 kD CD44-ICD protein.   The CD44-ICD-myc construct omitted the stop codon but 
was carefully designed to be in-frame so as to integrate the C-terminal myc sequence.  
The addition of the myc tag added 1.5 kD to the 15 kD size of the CD44-ICD.  The 
downstream primers used were: untagged CD44-ICD: 5ʹ′TTACACCCCAATCT 
TCATGTCCACATTC3ʹ′; and CD44-ICD-myc: 5ʹ′CGCCGGCGCACCCCAATCTTCATG 
TCCACATTC3ʹ′. 
 
The first step of the two-step cloning strategy used was to PCR-amplify the CD44-
ICD sequence using pCDM8-CD44H as a template, introducing the new Sal I and Not I 
sites in the process.  The PCR product was first sub-cloned into a pcDNA3.1/V5-His-
TOPO vector (Invitrogen) (Figure 6A).  This intermediate cloning step allowed for the 
generation of a large amount of CD44-ICD insert and, for more efficient restriction 
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digestion.   A sequential double restriction digest using Sal I and Not I restriction 
enzymes (Invitrogen) was performed to remove the CD44-ICD insert from the TOPO 
vector and achieve directional cloning into pCMV/myc/cyto vector (Figure 6B). 
 
1.1.2. Generation of GFP-CD44-ICD 
In order to generate a CD44-ICD containing a GFP at the N-terminal (5ʹ′ end), the 
PCR-amplified CD44-ICD sequence including the stop site (shown above) was cloned 
into a pcDNA3.1/NT-GFP-TOPO vector (Invitrogen) to generate a GFP (Green 
Fluorescent Protein) epitope-tagged fusion protein with CD44-ICD.  Since the GFP tag 
in this plasmid is upstream to the multiple cloning site, this plasmid will also provide an 
efficient start site to express the CD44-ICD peptide.   As such, it was again important to 
engineer the CD44-ICD insert to be properly subcloned in-frame.  When the GFP is 
expressed as a protein, it adds ~30 kD of molecular size to the fusion protein.   
Therefore, the GFP-CD44-ICD fusion protein was expected to be ~45 kD. 
 
1.1.3. Generation of CD44-ICD-EGFP 
In order to generate a CD44-ICD containing an EGFP (Enhanced Green 
Fluorescent Protein) at the C-terminal (3ʹ′ end), the CD44-ICD was subcloned into a 
pEGFP-N2 vector (Clontech, Mountain View, CA).  Because the EGFP tag is C-terminal 
to the insert, a start site must be provided and the insert has to be in-frame with the 
EGFP. To achieve successful protein expression of the CD44-ICD in this plasmid, the 
untagged CD44-ICD previously cloned was PCR amplified including the start site and 
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Kozak sequence from the pCMV/myc/cyto vector and subcloned into a pcDNA3.1/V5-
His-TOPO vector (Figure 7A). 
 
Primers were carefully designed to amplify sequence upstream the vector ATG 
start site and include appropriate restriction sites that could be used for directional 
cloning into the pEGFP-N2 vector.  The upstream primer was engineered to include a 
Hind III 5’CAAGCTTTAACTAGAGAACCCGTGGCC3’, and the downstream primer 
included an Apa I site:  
5ʹ′TTCGGGCCCCACCCCAATCTTCATGTCCACATTCTGCAGGTTG3ʹ′.  The PCR 
product was subcloned into pcDNA3.1/V5-His-TOPO vector and digested with Hind III 
and Apa I restriction enzymes and subcloned into pEGFP-N2 vector.   The expected 
size of the CD44-ICD-EGFP fusion protein was 45 kD (Figure 7B). 
 
1.1.4. Generation of RFP-CD44-ICD 
In order to introduce a red fluorescence tag that was N-terminal to CD44-ICD, a 
pDsRed2-C1 vector (Clontech) was used to subclone the CD44-ICD.  Taking the 
previously cloned GFP-CD44-ICD, a double digest using Hind III and Apa I restriction 
enzymes was used to cut the CD44-ICD insert from the plasmid, and ligated into an 
open pDsRed2-C1 vector.  After ligation, the plasmid was transformed into chemically 
competent TOP 10 cells and grown in agar plates containing 100 µg kanamycin. 
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1.1.5. Generation of CD44-FL-EGFP 
Figure 7:  Cloning strategy to generate CD44-ICD-EGFP.  A. Primers were designed 
with Hind III and Apa I sites to amplify the previously cloned CD44-ICD-myc, including the 
start site from the pCMV/myc/cyto vector.  The PCR product was then subcloned into a 
pcDNA3.1/V5-His-TOPO vector.  B. A double restriction digest using Hind III and Apa I 
removed the CD44-ICD from the TOPO vector.   The insert was subcloned into an open 
pEGFP-N2 vector to generate a CD44-ICD with an EGFP (Enhanced Green Fluorescent 
Protein) tag at the C-terminus, the CD44-ICD-EGFP. 
 
A. 
B. 
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1.1.5. Generation of CD44-FL-EGFP 
In order to visualize the endogenous fragmentation of a full-length CD44 (CD44-
FL) and the generation of a CD44-ICD in situ, a CD44-FL-EGFP expression plasmid 
was prepared in our laboratory, similar to one described above for CD44-ICD-EGFP.   
To perform this task, CD44-FL within the pCDM8 plasmid was PCR amplified and 
subcloned in-frame by directional cloning into the pEGFP-N2 plasmid.   An upstream 
primer was designed that included a start/Kozak sequence of the CD44-FL as found in 
the pCDM8 plasmid with the addition of a Hind III restriction site in the 5ʹ′ end: 
5ʹ′CAAGCTTTCGCTCCGGACACCATGGACAAG 3ʹ′.  The downstream primer was the 
same as the one used to subclone the CD44-ICD into the pEGFP-N2 plasmid; namely, 
one that provided in-frame sequence with the C-terminal EGFP and an Apa I restriction 
site: 5ʹ′TTCGGGCCCCACCCCAATCTTCATGTCCACATTCTGCAGGTTG3ʹ′. 
 
The CD44-FL was PCR amplified using a pCDM8-CD44H as a template and 
then subcloned into an intermediate pcDNA3.1/V5-His-TOPO plasmid (Invitrogen).   
The CD44-FL insert was then digested using Hind III and Apa I restriction enzymes 
(Invitrogen) and the gel-purified product ligated into a digested pEGFP-N2 vector.  The 
approximate expected size of the CD44-FL-EGFP fusion protein containing the EGFP 
epitope tag at the C-terminus is ~120 kD fusion protein. 
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1.1.6. Generation of GFP-Smad1 
Primers were designed to PCR-amplify and subclone human Smad1 from a 
Smad1 template previously cloned into a pcDNA 3.1/myc-His A (Invitrogen).  The 
upstream primer included the ATG start site for Smad1: 5ʹ′GCAGATATCGGT 
ACCATGAATGTGA3ʹ′ and the downstream primer included the stop site since the GFP 
tag is N-terminal to the insert: 5ʹ′GCATATTCAGATCCTCTTCTTAGATGAG3ʹ′.  Because 
the PCR product is larger than 1,000 bp (1471 bp), a high fidelity Pfx Platinum Taq 
polymerase (Invitrogen) was used for amplification, and dATP-tails were added after the 
amplification step.    This last step provided the necessary 3ʹ′dA residues necessary for 
TOPO TA cloning the Smad1 PCR product into a pcDNA3.1/NT-GFP-TOPO vector. 
 
Each reaction included 5 µl of Pfx amplification buffer, 1.5 µl of dNATPs, 1 µl of 
MgSO4, 0.5 µl of each upstream and downstream primer, 1 µl of DNA template, 0.5 µl of 
high fidelity Pfx Platinum Taq polymerase and 40 µl of sterile water.  The cycling 
conditions were: initial denaturation of at 94ºC for 2 minutes, followed by 30 cycles of 15 
second denaturation at 94 ºC, 30 seconds annealing at 55 ºC and 1 minute extension at 
68 ºC.  After amplification, the vial was briefly placed on ice and 0.5 µl of ampli Taq 
DNA polymerase (Invitrogen) was added and then incubated at 72ºC for 10 minutes and 
proceeded to cloning immediately. 
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1.1.7. Generation of Smad1-EGFP 
To generate a Smad1 containing an EGFP (Enhanced Green Fluorescent 
Protein) tag at the C-terminus, a previously cloned human Smad1 in a pcDNA 3.1/myc-
His A plasmid was digested directly with Hind III and Apa I restriction enzymes for 
directional cloning into pEGFP-N2 plasmid.   The product was gel purified and ligated to 
a Hind III and Apa I digested pEGFP-N2 vector.  The EGFP tag adds ~30 kD to the 60 
kD Smad1 protein to create a ~90 kD fusion protein Smad1-EGFP. 
 
1.2. Conventional Polymerase Chain Reaction (PCR) 
A typical PCR reaction included 2 µl of template DNA, 1 µl of each upstream and 
downstream primers (0.3 µM each), 25 µl of AmpliTaq Gold PCR Master Mix (Applied 
Biosystems), and 21 µl of sterile water.  The cycling conditions had an initial 
denaturation for 2 minutes at 95ºC and a 2 minute annealing cycle at 72 ºC, followed by 
thirty amplification cycles, each of 1 minute denaturation at 95 ºC, 1 minute annealing at 
60 ºC and 1 minute extension at 72ºC.  Amplifications were performed using a PTC-
100TM Programmable Thermal Controller thermocycler (MJ Research, Inc., Watertown, 
MA) or using a Mastercycler Pro S thermocycler (Eppendorf, Fisher Scientific.). An 
aliquot of the amplification products were analyzed by electrophoresis on 1.2% agarose 
gels with products detected by staining with ethidium bromide. 
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1.3. Agarose gel electrophoresis 
Plasmid DNA, PCR products and restriction digests were analyzed by 
electrophoresis on 1% (for bands larger than 500 bp) or 1.5% (for bands smaller than 
500 bp) agarose gels (IBI scientific, Peosta, IA) prepared in Tris-Borate EDTA (TBE) 
buffer containing 5 µl of ethidium bromide.  Electrophoresis conditions for most agarose 
gels were typically 1 hour at 80 V.  The stained products were scanned and quantified 
using a fluorimaging system (Chemi-Doc, Bio-Rad, Hercules, CA) and compared to a 
100 bp DNA ladder standard (ID Labs, Carlsbad, CA).   Band intensities of digitized 
images were quantified using Quantity-One software (Bio-Rad). 
 
1.4. Cloning and transformation 
Following PCR amplification, CD44-ICD was sublconed into a pcDNA3.1/V5-His-
TOPO vector using the TOPO® cloning reaction kit provided with the vector.  Each 
reaction consisted of 2 µl of fresh PCR product, 1 µl of salt solution, 1 µl of sterile water 
and 1 µl of TOPO® vector.  The reaction was incubated for five minutes at room 
temperature, and then placed on ice and proceeded to One shot® chemical 
transformation (Invitrogen). 
 
Two µl of the TOPO® cloning reaction were mixed into a vial of One shot® TOP10 
Chemically Competent E. coli (Invitrogen), and incubated on ice for 5 minutes.  Cells 
were heat-shocked for 30 seconds in a 42ºC water bath, and immediately transferred to 
ice for one minute.  A 250 µl aliquot of room temperature super optimal culture (SOC) 
  37 
media was added to the cells and incubated at 37ºC while shaking horizontally at 200 
rpm for one hour.  Different volumes (25 µl, 50 µl, 75 µl and 100 µl) were spread onto 
pre-warmed agar plates containing ampicillin (100µg/ml) and incubated at 37ºC 
overnight.  Five colonies were randomly selected for DNA purification and analysis. 
 
1.5. Plasmid preparations 
1.5.1. Miniprep: 
Selected colonies were stabbed with an applicator stick, mixed with 4 ml of Luria 
Broth (LB) media containing ampicillin (100µg/ml) and grown overnight at 37ºC with 
shaking.  Plasmid DNA was isolated and purified using a miniprep kit (Qiagen, Hilden, 
Germany).  Two milliliters of the cultured bacteria were centrifuged at 6,800 x g for 3 
minutes in a conventional table-top microcentrifuge at room temperature.  The bacterial 
pellet was re-suspended in 250 µl of re-suspension buffer (buffer P1) by pipetting up 
and down several times.  A 250 µl aliquot of lysis buffer (buffer P2) was added to the 
mix and inverted 4-6 times vigorously.  Next, 350 µl of neutralization solution (buffer N3) 
was added and mixed thoroughly by vigorously inverting the tube 4-6 times, and 
centrifuged at 13,600 x g for 10 minutes. 
 
The supernatant was added to a spin column provided in the kit and centrifuged for 
1 minute.  The flow-through was discarded and the spin column was washed by adding 
500 µl of buffer PB and centrifuged for an additional minute.  The spin column was 
washed with 750 µl of wash buffer (buffer PE) and centrifuged for another minute.  The 
column was placed in a new 1.5 ml microcentrifuge tube, and 50 µl of elution buffer 
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(buffer EB) was added to the spin column and incubated for 1 minute at room 
temperature to elute the DNA.  The tube was centrifuged for an additional minute at full 
speed (~13,000 x g) and the 50 µl of eluted DNA was collected in the centrifuge tube.   
 
To estimate the yield, 10 µl of plasmid DNA were diluted into 490 µl of water and the 
absorbance at 260 and 280 nm was read on a spectrophotometer.  To determine the 
purity of the sample, the 260/280 ratio was expected to be between 1.7-1.9.  Ratios 
below 1.7 suggest that the sample is contaminated with protein, and ratios above 1.9 
suggest that the sample may contain substantial amounts of RNA.  The amount of 
plasmid DNA was calculated by multiplying the dilution factor, absorbance reading at 
260 nm and extinction coefficient of DNA (50 µg/ml).  Typical DNA concentration varies 
between 0.1-0.3 µg/ml. 
 
1.5.2. Maxiprep: 
To purify higher plasmid DNA from higher volumes of bacteria, a maxiprep DNA 
purification kit was used (Qiagen).  A 200 µl aliquot of inoculated bacteria grown for a 
miniprep was added to 100 ml of LB media containing ampicillin (100 µg/ml) and 
incubated overnight at 37ºC while shaking vigorously.  The bacteria were harvested by 
centrifugation at 3,000 x g for 15 minutes at 4˚C.  The pellet was re-suspended in 10 ml 
of re-suspension solution (buffer P1) and mixed by pipetting up and down.  A 10 ml 
aliquot of lysis buffer (buffer P2) was added and mixed by vigorously inverting the 
sealed tube 4-6 times, and incubated at room temperature for 5 minutes. 
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Briefly, 10 ml of pre-chilled neutralization solution (buffer P3) was added to the 
lysate and mixed immediately by vigorously inverting 4-6 times.  The lysate was 
immediately poured into the barrel of a filter cartridge with a cap screwed to the outlet 
nozzle provided in the kit, and incubated at room temperature for 10 minutes.  The cap 
was removed from the cartridge and the plunger was gently inserted to filter the cell 
lysate, which was collected in a sterile 50 ml tube.  Approximately 25 ml of cell lysate 
was recovered after filtration.  Then 2.3 ml of buffer ER was added to the filtered lysate, 
mixed by inverting the tube 10 times and incubated on ice for 30 minutes. 
 
During the 30 minutes incubation time, a QIAGEN-tip 500 provided in the kit was 
equilibrated by adding 10 ml of equilibration buffer (buffer QBT) and allowed to empty 
by gravity flow.  After the 30 minutes incubation was over, the filtered cell lysate was 
added to the QIAGEN-tip 500 and allowed to enter the resin by gravity flow.  The 
QIAGEN-tip 500 was washed twice with 30 ml of wash buffer (buffer QC), and then 15 
ml of elution buffer (buffer QN) was added to elute the DNA, which was collected in a 50 
ml endotoxin-free tube.  To precipitate the DNA, 10.5 ml of room-temperature 
isopropanol were added to the eluted DNA, mixed and centrifuged at 13,000 x g for 30 
minutes at 4ºC.  The DNA pellet was washed with 5 ml of endotoxin-free room 
temperature 70% ethanol, and centrifuged at 11,000 x g for 10 minutes.  The pellet was 
air-dried for about 10 minutes and re-dissolved in 400 µl of endotoxin-free buffer TE. 
 
To estimate the yield, 10 µl of plasmid DNA were diluted into 490 µl of water and the 
absorbance at 260 and 280 nm was read on a spectrophotometer.  To determine the 
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purity of the sample, the 260/280 ratio was expected to be between 1.7-1.9.  Ratios 
below 1.7 suggest that the sample is contaminated with protein, and ratios above 1.9 
suggest that the sample may contain substantial amounts of RNA.  The amount of 
plasmid DNA was calculated by multiplying the dilution factor, absorbance reading at 
260 nm and extinction coefficient of DNA (50 µg/ml).  The DNA concentration of 
plasmids isolated by this maxiprep method varied between 0.5-2.0 µg/ml. 
 
1.6. Restriction digests 
Restriction endonuclease digestions were performed to cut inserts from 
plasmids, to detect the presence of an insert in a plasmid, or to verify the orientation of 
the insert in the plasmid.  All restriction enzymes were from Invitrogen and buffers used 
were those provided with the enzymes (numbered 1-10). The restriction digest products 
were visualized on 1-1.5% agarose gels stained with ethidium bromide. 
 
1.6.1. Sal I and Not I 
Because these two enzymes work under different buffer conditions, a sequential 
double digest was performed for buffer adjustment. This double sequential digest was 
used to remove the CD44-ICD insert from the pcDNA3.1/V5-His-TOPO vector and 
subclone into the pCMV/Myc/cyto vector.  To set up the digest, 2 µl of plasmid (~1-4 µg) 
was mixed with 2 µl of Not I restriction enzyme, 2 µl of buffer 3 (50 mM Tris-HCl, 10 mM 
MgCl2, 100 mM of NaCl, at 8.0 pH), 11.3 µl of water, and incubated at 37ºC for 1 hour.  
After this incubation, 2µl of Sal I restriction enzyme and 0.7 µl of buffer 10 (100 mM 
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Tris-HCl, 10 mM MgCl2, 150 mM of NaCl, at 7.6 pH) was added to the mixture and the 
mixture incubated at 37ºC for an additional 2 hours or overnight. 
 
1.6.2. Pvu II 
This digest was used to verify whether the CD44-ICD was properly cloned into the 
TOPO vectors in the 5’→3’ direction.  Pvu II cuts within the CD44-ICD once, between 
bases 175 and 176 (G-C) of the 233 bp cytotail insert, and three times within the 
pcDNA3.1/V5-His-TOPO vector.  If the CD44-ICD was successfully cloned in the 5’→3’ 
direction, a 472 bp and a 3119 bp bands would be produced, whereas a 536 bp and 
3005 bp bands would appear if the ICD was cloned in the 3’→5’ direction. 
 
Each reaction included 1 µl of plasmid DNA, 2 µl of Pvu II restriction enzyme, 2 µl of 
buffer 6 and 15 µl of sterile water.  The digest was incubated for 2 hours or overnight at 
37ºC. 
 
1.6.3. Hind III and Apa I 
This double restriction digest was used for directional cloning of both CD44-ICD 
and CD44-FL into the pEGFP-N2 vector and pDsRed2-C1.  Because both restriction 
enzymes were compatible, so there was no need to perform a sequential digest.  Each 
reaction included 2 µl of DNA, 2 µl of Hind III restriction enzyme, 1 µl of Apa I restriction 
enzyme, 2 µl of buffer 4 and 13 µl of sterile water.  The sample was incubated at 37 ºC 
for 2 hours or overnight. 
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1.7. Gel extraction and purification 
The 233 bp fragment CD44-ICD was visualized on 1.5 % agarose gels stained with 
ethidium bromide and excised (under UV light and behind a light shield) using a sterile 
scalpel and purified using QIAEX II Agarose Gel Extraction kit (Qiagen).  The gel slice 
was placed in a sterile microcentrifuge tube and weighed.  Three volumes of buffer QX1 
were added to 1 volume of gel (i.e. 300 µl of buffer QX1 were added for each 0.1 g of 
gel), followed by 30 µl of QIAEX II solution.  The mix was incubated at 50ºC for 10 
minutes, vortexing every 2 minutes to keep QIAEX II in suspension to melt the agarose.  
The sample was then centrifuged for 1 minute at 12,000 x g, and the supernatant was 
carefully removed with a pipette to separate the DNA (pellet).  The pellet was washed 
once with 500 µl of buffer QX1 and twice with 500 µl of buffer PE, with a centrifuge step 
of 1 minute at 12,000 x g in between washes. 
 
The pellet was allowed to air-dry for 10-15 minutes until it became white.  Then, 20 
µl of sterile water was added, the tube vortexed to re-suspend the pellet, and incubated 
for 5 minutes at room temperature.  The tube was centrifuged for an additional minute 
under same conditions. The supernatant containing the purified DNA was then 
transferred to a new sterile tube and used for ligation. 
 
1.8. DNA ligation of inserts into plasmids 
In order to ligate the purified CD44-ICD insert into the pCMV/myc/cyto vector, the 
same double sequential restriction digest was performed on the empty vector to open 
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up the multiple cloning site between the Sal I and Not I restriction sites.  Once the empty 
vector was digested and the CD44-ICD insert was purified, 2.4 µl of the open vector 
was combined with 12 µl of the purified insert (5 fold insert: vector), 1 µl of T4 DNA 
ligase enzyme (Invitrogen), 4 µl of T4 DNA ligase buffer and 0.6 µl of sterile water and 
incubated overnight at room temperature.  After ligation, the plasmid was transformed 
into chemically competent One Shot® TOP10 E. coli bacteria. 
 
1.9. Characterization of plasmid constructs 
Once colonies were detected following transformation, typically 5 random, well 
spaced colonies would be expanded as minipreps.   The plasmids purified from these 
minipreps would then be characterized by a variety of methods to insure the presence 
and orientation of the insert.  Most often, a restriction digest was performed using the 
restriction sites engineered into the PCR primers that were used to PCR amplify the 
insert.  This method was used to verify whether the insert was successfully cloned in the 
target vector. 
 
Alternatively, the plasmid would be used as a template for PCR amplification using 
these same PCR primers and the presence of insert detected as a PCR product on 
agarose gels.   In addition, a single digest with Pvu II, which cuts once within the CD44-
ICD insert, was used to verify the cloning direction of CD44-ICD as, discussed in 1.6.2.   
Plasmids were also characterized by DNA sequencing (Department of Biology Core, 
ECU) using either universal primers (T3, T7 and SP6 sequences within expression 
plasmids) or the PCR amplifying primers that we supplied.    Lastly, plasmids were 
  44 
transfected into different cell lines and protein expression of the insert detected by 
immunohistochemistry or western blotting. 
 
2. Site directed mutagenesis 
In order to introduce site directed mutations into a sequence, the GeneTailor™ Site 
Directed Mutagenesis System from Invitrogen was used.  This system allows 
introduction of specific CD44-ICD mutations by using pCMV/myc/cyto-CD44-ICD vector 
as a template and incorporating the desired mutation site within the upstream primer.  
Three point mutations where targeted in the CD44-ICD sequence to produce a non-
relevant peptide, a CD44-ICD with a mutated ERM binding domain and a CD44-ICD 
with a mutated ankyrin binding domain. 
 
2.1. Mutation strategies 
2.1.1. Point mutation used to generate a non-relevant control peptide 
As a negative control, a ~15 kD non-relevant peptide was generated to ensure 
that any biological changes resulting from CD44-ICD over-expression were specific to 
the CD44-ICD sequence and not due to over-expression of a 15 kD fragment.  Using 
pCMV/myc/cyto-CD44-ICD vector as a template, a single base pair was added at the 
beginning of the coding sequence of the CD44-ICD, creating a frame-shift that was 
predicted to translate a new, unique irrelevant protein but one with identical translation 
initiation properties of the CD44-ICD construct. 
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Computer-based translation predictions suggested that the frame shift would 
generate an open reading frame that would encounter a stop codon close to the natural 
stop codon of CD44-ICD.   Thus, the control peptide would differ in size from the CD44-
ICD by only a few amino acids.  The mutation primer (extra dG shown in bold) was: 
5ʹ′CCCGTGGCCACCATGGCCCAGGGTGCAGCTGCAG3ʹ′ and the partially-overlapping 
opposite strand primer was: 5ʹ′TGGGCCATGGTGGCCACGGGTTCTCG3ʹ′. 
 
2.1.2. Point mutation used to destroy CD44 ERM binding domain mutations 
Yonemura and colleagues believed that positively charged juxta-membrane 
amino acids in the cytoplasmic sequence of proteins known to bind to ERM proteins, 
are necessary for proper ERM binding.  In the CD44 sequence, the three lysine (K) 
residues located just distal to the transmembrane domain are believed to be crucial for 
CD44 binding to ERM, as mutating the K298K299K300 to Q298I299N300 resulted in no CD44-
ERM binding (Yonemura et al., 1998). For this reason, our mutating strategy was 
targeted to the positively charged residues KKK to QIN, as suggested by the previous 
study. 
Using pCMV/myc/cyto-CD44-ICD vector as a template, an upstream primer 
containing the ERM binding domain mutation (bold) was designed: 
5ʹ′AGTCGAAGAAGGTGTGGGCAGCAGACAAACCTAGTGATCAA3ʹ′ and the partially-
overlapping downstream primer was: 
5ʹ′CTGCCCACACCTTCTTCGACTGTTGACTGC3ʹ′. 
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2.1.3. Point mutation used to destroy CD44 Ankyrin binding domain mutations 
Studies addressing the crucial amino acids in the ankyrin binding domain of 
CD44 included truncated versions of the CD44 sequence rather than point mutations, 
and therefore to our knowledge, the critical amino acids that serve as binding sites are 
still unknown.  We sought to target plausible residues within the putative ankyrin binding 
domain of CD44.  Given that a cluster of three positively charged amino acids were 
determined to be crucial in CD44 binding to ERM adaptor proteins, we targeted twin 
basic residues in the ankyrin binding domain sequence of CD44 as a reasonable first 
approach: Arg313-Lys314.  Following a similar strategy to the point mutations of the ERM 
binding domain, we mutated these two residues to Ile313-Asn314 by using 
pCMV/myc/cyto-CD44-ICD vector as a template, an upstream primer containing the 
ankyrin binding domain mutation (bold): 
5ʹ′AATGGAGCTGTGGAGGACACAAACCCAAGTGGACTC3ʹ′ and the partially-
overlapping downstream primer was: 5ʹ′GTCCTCCACAGCTCCATTGCCACTGTTG3ʹ′. 
 
2.2. Methylation reaction 
An initial step in the site-directed mutagenesis procedure is methylation of the 
parental, target plasmid DNA.   In this way, the daughter strands that are generated and 
contain the mutation can be separated from the original template DNA by selective 
degradation of methylated DNA.  The DNA methylase enzyme, methylates cytosine 
residues throughout the double-stranded plasmid DNA sequence.  The plasmid DNA 
was methylated by mixing 1 µl (100 ng) of plasmid DNA, 1.6 µl of methylation buffer, 1.6 
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µl of 10x SAM, 1 µl of DNA methylase and 10.8 µl of sterile water, and incubated at 
37ºC for one hour. 
 
2.3. Mutagenesis reaction and PCR parameters 
The next step in site directed mutagenesis included a PCR reaction using the 
methylated plasmid DNA as a template and the partially-overlapping primers containing 
the mutation site.  A high fidelity Platinum Taq DNA polymerase was recommended for 
plasmids up to 8 kb, which would include our pCMV/myc/cyto at 4.9 kD.     Each PCR 
reaction included 5 µl of 10X high fidelity PCR buffer, 1.5 µl of 10 mM dNTP, 1 µl of 50 
mM MgSO4, 1.5 µl of each upstream and downstream primer, 2 µl of methylated 
plasmid DNA, 0.5 µl of high fidelity Platinum Taq DNA polymerase and 37 µl of sterile 
water.  The PCR parameters included an initial denaturation for 2 minutes at 94ºC, 
followed by 20 amplification cycles, each of 30 seconds denaturation at 94 ºC, 30 
seconds annealing at 55ºC and a 5 minute (1 minute/ 1 kb DNA) extension at 68ºC, 
followed by an additional 10 minute extension at 68ºC.   Amplifications were performed 
using a PTC-100TM Programmable Thermal Controller thermocycler (MJ Research, 
Inc., Watertown, MA). 
 
2.4. Transformation of mutated plasmids and destruction of template DNA 
One Shot® MAX Efficiency® DH5á™-T1R competent cells were used for 
transformation of the amplified mutated plasmid.  These bacteria were used because 
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they selectively degrade methylated plasmid DNA.  Thus, any positive colonies will be 
derived from bacteria containing non-methylated plasmid.   Each vial of cells (1 per 
transformation) was thawed on ice for 5-7minutes, and 2 µl of the mutagenesis PCR 
product was added to a vial of cells and mixed by tapping gently. 
 
The vial was incubated on ice for 10 minutes and then heat shocked for 30 seconds 
at 42ºC.  The vial was then placed on ice for an additional minute, and 200 µl of pre-
warmed SOC media was added to the cells.  Cells were incubated at 37ºC while 
shaking horizontally at 200 rpm for one hour.  Different volumes (25 µl, 50 µl, 75 µl and 
100 µl) were spread in pre-warmed agar plates containing ampicillin (100µg/ml) and 
incubated at 37ºC overnight.  Five colonies were randomly selected for plasmid 
purification and analysis. 
 
3. Cell Culture and Design of Cell-Based Experiments 
3.1. Bovine articular chondrocytes 
3.1.1. Tissue digestion and cell isolation 
Bovine articular chondrocytes (BAC) were isolated from the 
metacarpophalangeal joints of 18-24 month old bovine steers that were obtained from a 
local slaughterhouse and stored for 1-3 days until dissection.   Hooves were washed, 
skinned and sanitized with 70% ethanol.  After being placed in a hoof holder under a 
dissection hood, an incision was made to cut the exposed anterior and lateral ligaments 
and the synovial capsule.   Using a sterile scalpel, 10 mm deep slices were removed 
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from both upper and lower condyles and placed into sterile cups containing 0.9% NaCl2 
solution. After removing most of the articular cartilage, the dry weight was obtained and 
the tissue was then digested for one hour in 0.4% pronase (EMD scientific, San Diego, 
CA) solution prepared in serum free Dulbeco’s Modified Eagle’s Medium/Ham’s F12 
medium (Mediatech, Manassas, VA) at 37 ºC in a 5% CO2 environment while stirring, in 
order to isolate the cells from the complex extracellular matrix. Tissue was washed 
twice with serum free media and then incubated overnight in 0.025% collagenase P 
(Roche, Indianapolis, IN) solution under the same conditions. 
 
The tissue/collagenase mixture was next pushed through a 100 µm strainer to 
remove large debris and the liberated cells collected in a sterile 50 ml tube.  Cells were 
centrifuged for 5 minutes at 1,300 x g and washed twice in serum free DMEM/Ham’s 
F12 medium.  After the second wash, cells were pushed through a 40 µm cell strainer 
and cells were centrifuged for another 5 minutes.  The cell pellet was re-suspended in 
chondrocyte feeding media (CFM), which is prepared in DMEM/Ham’s F12 medium 
containing 10% Fetal Bovine Serum (Hyclone, South Logan, UT), 1 ug/ml ascorbic acid 
and primocin.  Cells were counted using a hemocytometer and either plated as a high 
density monolayer (2.0 x 106 cells/cm2) or cultured in alginate beads. 
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3.1.2. Alginate beads culture 
After the last centrifugation step in the chondrocytes isolation, 4x106 cells were 
re-suspended in 1 ml of an 1.2% alginate solution (Kelco, Chicago, IL) prepared in 150 
mM NaCl.  The alginate/cell mix was passed through a 22 gauge syringe and collected 
in 30 ml of 102 mM calcium chloride prepared in 0.9% NaCl2 to form small alginate 
beads, each containing approximately 40,000 chondrocytes per bead.  Beads were 
transferred to a culture dish containing CFM and incubated for at least 48 hours. 
 
In order to release cells from the beads to use for experiments, beads were 
removed from CFM and washed twice in serum free culture media.  The beads were 
then re-suspended in a dissociation buffer (0.055 M sodium citrate, 0.15 M NaCl, pH 
6.8) and mixed gently until beads were no longer visible.  Released cells were collected 
by centrifugation for 5 minutes at 1,300 x g and washed twice with sterile PBS.  Cells 
were plated in CFM as needed for experiments. 
 
3.1.3. Passaging of BACs to obtain dBACs 
Cells that were not grown in alginate bead cultures, were plated at either high 
density (2.0 x 106 cells/cm2) or low density (0.5 x 106 cells/cm2) in 10% FBS-CFM.  High 
density cultures were able to preserve the typical round chondrocyte morphology for 
several days, and therefore were used for primary chondrocyte experiments.  When 
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cells were plated at low density, they slowly began to lose the cortical cytoskeleton and 
began to de-differentiate into more fibroblast-like cells (dBACs). 
 
In some studies the dBACs were passaged using trypsin and grown at low 
density.  Passage number was recorded and labeled P0 for primary BAC cultures (no 
passages) or P1, P2, P3 for consecutive passages of dBACs. 
 
3.2. Other cell lines used 
Several other cell lines were used in conjunction with BACs.   COS-7 cells (African 
green monkey kidney epithelial cells, obtained from American Type Culture Collection), 
a SV40-immortalized cell line, allow for a high level of transfection efficiency and high 
protein expression of plasmid constructs with an SV40 promoter, which allows 
substantial replication of the vector by the large T-antigen.   Another useful property of 
COS-7 cells is the lack endogenous CD44 expression (Jiang et al., 2002) eliminating 
background expression of endogenous CD44 isoforms or domains. 
 
Two chondrocyte-like cell lines were used in this study.  The rat chondrosarcoma 
cell line (RCS) was a continuous long term culture line derived from the Swarm rat 
chondrosarcoma tumor (Choi et al., 1971). The RCS cell line in the Knudson 
laboratories was a gift of Dr. James H Kimura (formerly of Rush University Medical 
Center) and represented an early clone of these cells that eventually became known as 
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long-term culture RCS (Kucharska et al., 1990). Another chondrocyte line used was the 
human immortalized chondrocyte line (C28/I2).  The C28/I2 cells were derived from 
SV40-immortalization of primary cultures of human juvenile costal chondrocytes and 
subsequent selection by suspension over agarose (Goldring et al., 1994). The C28/I2 
cells maintain some but not all phenotypic properties of adult chondrocytes while at the 
same time allowing continuous growth in culture and high transfection efficiency.  The 
C28/I2 cells were a generous gift from Dr. Mary Goldring, Hospital for Special Surgery, 
N.Y. 
 
All these cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Mediatech) containing 10% FBS (Hyclone) and 1% L-glutamine and penicillin-
streptomycin, and incubated at 37ºC in a 5% CO2 environment and passaged at 
confluence using 0.25% trypsin/ EDTA. 
 
4. Treatment of cells to induce/inhibit CD44 cleavage 
Cells grown in monolayer cultures in complete medium were switched to serum-free 
culture media and then treated overnight with 10 ng/ml of Interleukin-1β (IL-1 β) (R&D 
systems), 250 µg/ml of HA oligosaccharides from rooster comb HA (Sigma) or 10 nM of 
phorbol myristate acetate (PMA) to induce proteolysis of either endogenous or 
exogenous CD44. 
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In order to inhibit CD44 proteolytic cleavage in vitro, cells were detached from the 
monolayer using collagenase/pronase treatment for 3 hours and then plated overnight 
in culture media containing 1 µM of a general MMP inhibitor GM6001 (EMD chemicals) 
and/or 10µM of a γ-secretase inhibitor DAPT (EMD chemicals).  After treatment, cells 
were lysed and proteolytic cleavage was detected by western blotting. 
 
5. Hyaluronidase treatment 
Cells were plated in a monolayer for at least 24 hours.  A solution of 200 U/ml of 
bovine testicular hyaluronidase (HA’ase) or 5 U/ml of Streptomyces HA’ase (Sigma) 
prepared in serum free media was added to the monolayer for 90 minutes.  Cells were 
either lysed or fixed after treatment and compared to a non-treated control. 
 
6. Transient transfection 
Cell transfection was obtained by using nucleofection technology (Lonza, Germany), 
which allows delivery of plasmid DNA directly into the nucleus.  Cells were cultured to 
reach ~90% confluency and then detached from the plate surface by trypsin-EDTA 
treatment for 5 minutes, or in the case of BAC by pronase/collagenase (10 mg each) 
treatment for 1 hr in at 37oC in a humidified cell incubator.   Cells were then centrifuged 
for 5 minutes at 1,300 x g and the pellet was re-suspended in 10 ml of DMEM to 
perform a cell count. 
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Each transfection included 4 µg of plasmid DNA and 1x106 cells (2x106 cells for 
BACs) re-suspended in 100 µl of room temperature Amaxa Cell Line Nucleofector® Kit 
V reagent (for transfection of cell lines) or Amaxa Human Chondrocyte Nucleofector® Kit 
reagent (for BAC).  In some experiments, 1 µg of empty vector pEGFP-N2 plasmid was 
mixed with 3 µg of the desired plasmid DNA (total of 4 µg).  These conditions were used 
to estimate transfection efficiency when the desired plasmid carried no fluorescent label.  
The mixture was transferred to an Amaxa cuvette and immediately placed in the cuvette 
holder of the Amaxa Nucleofector® Device.   
 
The appropriate program was selected (COS-7, RCS, C28/I2 used A-024; BAC 
used U-028) and nucleofection initiated.   Immediately after nucleofection, 500 µl of pre-
warmed 10% FBS RPMI media (Mediatech) was added to the cuvette.  Using the 
provided plastic pipette, the transfected cells were transferred to a 6 well plate 
containing pre-warmed 10% FBS culture media, or CFM for BACs.   Twenty-four hours 
after transfection, the cells were observed using a Nikon TE2000 inverted phase-
contrast fluorescence microscope to estimate transfection efficiency.   Typically, cells 
were lysed 48 hours after transfections and lysates used for protein detection by 
western blotting. 
 
7. Stable transfection 
The Flp-In™ system from Invitrogen was used to create stable CD44-ICD 
transfectants in HEK-293 cells and RCS cells.  This system involves introduction of a 
Flip Recombination Target (FRT) site into the desired mammalian cell line, followed by 
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expression of a vector containing the gene of interest, which is then incorporated into 
the genome by using Flp recombinase-mediated DNA recombination at the FRT site.  
The HEK-293 cells were purchased from Invitrogen with an FRT site already cloned into 
their genome and available for use.  The RCS required stable transfection of a FRT site; 
generating a RCS FRT host cell line. 
 
7.1. FRT-ICD cloning strategy 
Our laboratory subcloned the CD44-ICD from the pCMV/myc/cyto-CD44-ICD 
vector that I generated, into a pcDNA5 shuttle vector (pcDNA5/FRT-CD44-ICD) for 
recombination with HEK-293-FRT and RCS-FRT host cell lines. 
 
7.2. FRT host cell lines 
The pFRT/lacZeo plasmid was stably transfected (following Amaxa transfection 
protocol) into the RCS host cell line.   Following transfection, the cells were cultured in 
10% FBS DMEM containing 100 ug/m	  of the selection reagent, zeocin.    Once the FRT 
site is integrated into the genome, the cells become zeocin resistant.   Even after 
selection, the HEK-293-FRT and RCS-FRT routinely cultured in 10% FBS DMEM still 
containing zeocin in 37ºC and 5% CO2 environment. 
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7.3. Transfection and expression of FRT-ICD in host cell lines 
Once the FRT host cell lines were selected by growing in 10% FBS DMEM 
containing zeocin, the cells were used to generate stable transfectants using the Flp-
In™ method designed by Invitrogen.  Briefly, 1 x106  HEK-293-FRT or RCS-FRT host 
cells were re-suspended in 100 µl of Amaxa Cell Line Nucleofector® Kit V reagent 
together with 4 µg of pcDNA5/FRT-CD44-ICD plasmid and 36 µg of pOG44.  The 
mixture was transferred to an Amaxa cuvette and transfected by Amaxa nucleofection 
using program A-024 (for both HEK-293-FRT and RCS-FRT cell lines).   Following 
nucleofection, the cells were mixed immediately with 500 µl of pre-warmed 10% FBS 
RPMI media and transferred to a 6 well plate containing pre-warmed 10% FBS DMEM 
media.  After 24 hours, fresh media was added. 
 
7.4. Selection of stable transfectants 
Forty-eight hours after transfection, the cells were trypsinized and split into a 6-well 
plates at less than 25% confluence.  Cells were cultured in hygromycin (200 µg/µl) 
containing media for several weeks, changing the media every 3-4 days.  The co-
transfected pOG44 provided expression of a FRT recombinase, an enzyme that 
catalyzed the homologous recombination of the FRT site (localized within the host cell 
genome) and the pcDNA5/FRT-CD44-ICD plasmid.   Once incorporated, the 
pcDNA5/FRT-CD44-ICD plasmid contains a hygromycin resistance, and therefore only 
successfully transfected cells containing this plasmid continue to grow. 
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8. Immunofluorescence staining 
Cells were fixed in 2% paraformaldehyde (PFA) for 30 minutes at 4ºC, quenched 
with 0.2 M glycine in PBS and then blocked in 1% bovine serum albumin (BSA, Sigma) 
in PBS for 30 minutes at room temperature or overnight at 4ºC.  Cells were 
permeabilized with 0.2% triton X-100 in TBS for 10 minutes at room temperature and 
then washed twice with PBS.  For antibody detection, cells were incubated with primary 
antibody for 1 hour at room temperature, washed twice with PBS and then incubated 
with a secondary antibody.  For staining of the actin cytoskeleton using rhodamine-
phalloidin (Invitrogen), cells were permeabilized and then incubated with rhodamine-
phalloidin (1:150 dilution in PBS) for 1 hr at room temperature, and then washed twice 
with PBS. 
 
After the last wash, cells were mounted in mounting media containing the blue 
fluorescence nuclear stain; 4ʹ′, 6-diamidino-2-phenylindole, dihydrochloride (DAPI, 
Molecular probes) and visualized using a Nikon Eclipse E600 microscope equipped with 
Y-Fl Epi-fluorescence (Melville, NY).  Images were taken digitally in real time using a 
Spot-RT camera (Diagnostic Instruments, Sterling Heights, MI) and processed using 
NIS Elements BR imaging software (Nikon, Lewisville, TX). 
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9. Assays to study pericellular coat retention 
9.1. Particle exclusion assay 
The particle exclusion assay was used to evaluate the ability of stable and 
transient CD44-ICD chondrocyte (BACs and RCS) transfectants to retain their 
pericellular matrix.  Cells were plated at 50% confluence in a 6-well plate under normal 
cell culture conditions.  The medium was then removed, and a 750 µl suspension of 
fixed horse red blood cells were added to each well.  The plate was placed under the 
inverted phase contrast microscope and allowed to settle for 15 minutes.  The small red 
blood cell particles settle onto the tissue culture substratum, but are restricted from a 
region surrounding the cell plasma membrane.   The otherwise translucent space 
between the plasma membrane and the red blood cells consists of cell-associated 
extracellular matrix, sometimes referred to as the “pericellular matrix”.   The live cells 
and their pericellular matrices were observed and imaged using a Nikon TE2000 
inverted phase contrast microscope. 
 
9.2. Hyaluronan Binding Protein (HABP) assay 
Since HA is a glycosaminoglycan with no core protein, it cannot be detected using a 
typical antibody approach.   Methods are available to visualize HA through the use of 
proteins that contain HA-binding sites known as link domains.   One popular, 
commercial product is biotinylated-HABP, a fragmented derivative of bovine 
aggrecan/link protein complex.    In this study, biotinylated-HABP was added to cultured 
cells to visualize HA within the pericellular matrix.   For this assay, transient or stable 
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CD44-ICD transfectants were plated on a 4-well chamber slide at 50% confluence and 
cultured for 24 hours.  The cells were fixed in 2% paraformaldehyde (PFA) for 30 
minutes at 4ºC, quenched with 0.2 M glycine in PBS and then blocked in 1% bovine 
serum albumin (BSA, Sigma) in PBS for 30 minutes at room temperature.  Biotinylated-
HABP (Seikagaku USA, Ijamsville, MD) at a 2 µg/ml concentration was added to the 
cells, and incubated for one hour at 4ºC. 
 
Cells were washed with PBS and then incubated with neutravidin-FITC (1:1,000) 
(Molecular Probes) in 1% BSA in PBS for 30 minutes at 4ºC.  The cells were then 
washed with PBS and mounted in mounting media containing DAPI, and visualized 
using a Nikon Eclipse E600 microscope equipped with Y-Fl Epi-fluorescence.  Images 
were captured digitally in real time using a Spot-RT camera and processed using NIS 
Elements BR imaging software (Nikon, Lewisville, TX). 
 
10. Protein analysis 
10.1. Preparation of total protein cell lysates from cell cultures 
Cultured cells were lysed using a commercial 1X lysis buffer (Cell Signaling) 
containing 1X protease and phosphatase inhibitors (Pierce).  For differential extractions 
or immunoprecipitation assays, other detergent buffers were used (below).  After 
removing the media, cells were scraped from the surface using sterile cell scrapers and 
200 µl (for each well of a 6 well plate) of lysis buffer with inhibitors were added to the 
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plate.  Cells were re-suspended in lysis buffer, transferred to a microcentrifuge tube and 
incubated on ice for 10 minutes.  Cells were then centrifuged at 13,600 x g for 10 
minutes at 4ºC and supernatant was collected as the cell lysate, and protein 
concentration was determined by protein concentration assay. 
 
10.2. Protein concentration assay 
Following cell lysis, a 25 µl aliquot per sample was used to determine the protein 
concentration using a BCA kit protein concentration assay (Pierce).  On a 96-well plate, 
9 aliquots of sequential 1:10 dilutions of Bovine Serum albumin (BSA) in lysis buffer 
were set up as a standard.  A working reagent was prepared by mixing 50 parts of BCA 
(bicinchoninic acid) reagent A with 1 part of reagent B, and then 200 µl of working 
reagent was added to each well.  The plate was incubated for 30 minutes at 37ºC and 
then the absorbance was read at 562 nm on a plate reader as the strong purple BCA 
reaction exhibits a strong linear absorbance at 562 nm with increasing protein 
concentrations. 
 
10.3. Gel electrophoresis and western blotting 
Depending on the experiment, equal protein (10-30 µg) or equal volumes of protein 
lysate were mixed with 10 µl of NuPAGE®  LDS sample buffer, 4 µl of NuPAGE (10X) 
reducing agent (for running gels under reducing conditions) and enough deionized 
water to add to a total of 40 µl per sample.  Samples were heated for 10 minutes at 
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70ºC and then loaded into a 4-12% NuPAGE® Novex® Tris-acetate gradient mini gel 
(Invitrogen).  Electrophoresis times were typically ~45 minutes at 200V at room 
temperature.  Running buffer was prepared by adding 50 ml of 20X NuPAGE®  MES 
running buffer to 950 ml of deionized water.  When running under reducing conditions, 
500 µl of NuPAGE® antioxidant was added to 200 ml of 1X NuPAGE® MES running 
buffer. 
 
Following electrophoresis, proteins within the acrylamide gel were transferred to a 
nitrocellulose membrane using a Criterion blotter apparatus (BioRad).  The gel was 
placed in a cassette between blotting paper and nitrocellulose membrane, and current 
applied at 100 V in 4ºC for 1 hour and 20 minutes.  The nitrocellulose membrane was 
blocked in 5% non-fat dry milk in Tris buffered saline containing 0.1% Tween 20 (TBS-
T) for 1 hour while shaking at room temperature.  The membrane was washed once in 
TBS-T for 10 minutes and then twice for 5 minutes at room temperature while shaking.  
The blot was incubated with primary antibody (table 1) prepared in 5% BSA-TBS-T 
overnight at 4ºC while shaking. 
 
The following day, the blot was again washed once in TBS-T for 10 minutes and 
then twice for 5 minutes at room temperature while shaking and then incubated with 
corresponding secondary antibody prepared in TBS-T for 30 minutes at room-
temperature while shaking.  The blot was washed once again, and detection was 
performed using enhanced chemi-luminescence (ECL) reagents (Invitrogen).   Often 
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reacted / detected blots would be re-probed using a different primary antibody.    To re-
use the same blot for another antibody reaction, the original antibodies and reagents on 
the blot were removed with stripping buffer containing glycine and aliphatic carboxylic 
acid (Invitrogen) for 15 minutes while shaking at room temperature.  The blot was then 
washed and blocked in 5% low fat dry milk and incubated overnight with a different 
primary antibody. 
 
10.4. Differential extractions 
Cells were lysed first in 200 µl of a light-detergent buffer containing 50 mM Tris-
HCl, 150 mM NaCl, 5 mM EDTA, 0.1% Igepal (previously known as NP-40) and 1X 
protease inhibitor cocktail (Pierce), and incubated on ice for 10 minutes.  Cells were 
then centrifuged for 10 minutes at 1,300 x g, and supernatant was collected as the “light 
extraction”.  The pellet was re-suspended in 200 µl of a harsher-detergent buffer 
containing 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.5% Igepal (previously known 
as NP-40), 1% Empigen and 1X protease inhibitor cocktail (Pierce) and incubated on 
ice for an additional 10 minutes.  Cells were then centrifuged for 10 minutes at 13,600 x 
g, and supernatant was collected as the “harsh extraction”.  Lysates were run side by 
side on a western blot, loading equal volume rather than equal protein. 
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10.5. Co-immunoprecipitations 
In most experiments, cells were lysed in 10 mM Tris, pH 7.5 with 2 mM EDTA, 1% 
triton X-100 and 1 x protease and phosphatase inhibitors (Duterme et al., 2009). In 
other select experiments, alternative lysis buffer detergent conditions were used as 
described in the Results section.   The cells were incubated on ice for 10 minutes and 
the centrifuged at 13,600 x g for 10 minutes at 4ºC, and the supernantant was collected 
as the cell lysate.  In order to immunoprecipitate the desired protein, magnetic protein G 
Dynabeads® (Invitrogen) were used.  The Dynabeads® stock solution was gently re-
suspended, and 50 µl transferred to a 0.5 ml microcentrifuge tube. The tube was placed 
on a specially designed magnetic microfuge tube holder (Invitrogen) and the 
supernantant was removed.  The magnetic beads were conjugated with the primary 
antibody by removal from the magnetic stand and adding / re-suspending 10 µg of a 
primary antibody diluted in 200 µl of PBS-tween 20 (PBS-T) with the magnetic beads.  
The antibody / bead mixture was allowed to incubate at room temperature while shaking 
for 10 minutes.  The antibody / bead mixture was placed on the magnetic stand and the 
supernatant was removed.  The conjugated beads were washed by gently pipetting in 
200 µl of PBS-T three times. 
 
In order to immunoprecipitate the target antigen, the tube was placed into the 
magnetic field and the wash supernatant was removed.  The beads-antibody were 
removed from the magnetic stand and re-suspended in 100 µl of cell lysate (~100-500 
µg) by gently pipetting and incubated while shaking at room temperature for 10 minutes.  
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The tube was placed back into the magnetic stand and supernatant was collected for 
further analysis (this portion is described as the “not bound” fraction).  The beads-
antibody-antigen complex was washed 3 times with 200 µl of PBS, separating the 
beads from the washing buffer in between by placement within or out of the magnetic 
field.  After the third wash, the beads-antibody-antigen complex were re-suspended in 
100 µl of PBS and transferred to a new tube. 
 
To elute the target antigen from the beads-antibody-antigen complex, the tube was 
placed into the magnetic stand and supernatant was removed.  Twenty µl of elution 
buffer (50 mM Glycine, pH 2.8) was added to the beads-antibody-antigen complex 
along with 10 µl of NuPAGE®  LDS sample buffer, 4 µl of reducing agent and 6 µl of 
deionized water, and incubated 10 minutes at 70ºC.  The tube was placed into the 
magnetic stand once again, and the supernatant was collected and loaded into a 4-12% 
NuPAGE® Novex® Tris-acetate gradient mini gel and analyzed by western blot analysis 
(this portion is described as the “bound” or “eluted” fraction). 
 
10.6. HRP conjugation of primary antibodies 
Several antibodies were conjugated with horseradish peroxidase (HRP) to avoid 
cross-reactivity with immunoglobins of other species in co-immunoprecipitation assays 
by avoiding the need of using secondary reagents.  Table 1 has a summary of all HRP-
conjugated antibodies used in this study.  Primary antibodies were conjugated using a 
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Lightning-Link HRP Conjugation Kit from Innova Biosciences, which allows rapid 
labeling of primary antibodies in two simple steps.  First, 100 µg of antibody was mixed 
with 1 µl of LL-Modifier reagent for every 10 µl of antibody used.  Then, the antibody 
mixed with the LL-Modifier was added to 1 vial of Lightning-Link mix and gently pipette 
twice.  The mix was incubated 3 hours or overnight at room temperature, and after 
incubation, 1 µl of LL-quencher was added for every 1 µl of antibody used.  The HRP-
conjugated antibody was ready to use after 30 minutes following addition of the LL-
quencher solution. 
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Table 1: Summary of all antibodies used in this study. Important features and 
details of antibodies used in this study are included in a tabular format.  Included are: 
antibody name, species in which the antibody was generated (source), typical dilution of 
primary antibody stock used (concentration), name and dilution of the associated 
secondary antibody and, the name and molecular size (by western blot analysis) of 
proteins detected.    The stock solutions of primary and secondary antibodies were 
diluted in PBS with 5% BSA. 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 3: RESULTS 
  
In articular cartilage, as in many other tissues, cell-matrix interactions are vital to 
maintain cartilage homeostasis.  CD44 is a cell surface receptor that supports 
communication between the cell and the extracellular matrix.   As a transmembrane 
receptor, CD44 binds to the extracellular macromolecule HA, and to the actin 
cytoskeleton inside the cell.  Healthy interactions between CD44 and HA are crucial to 
maintain a balance between synthesis and degradation of extracellular matrix 
components.  In certain pathological conditions such as cancer and metastasis (Cichy 
and Pure, 2003; Guo et al., 1994; Lammich et al., 2002; Masson et al., 1999; Murakami 
et al., 2003; Okamoto et al., 1999a; Okamoto et al., 2001; Pelletier et al., 2006; Yamane 
et al., 1999) and rheumatoid arthritis (Haynes et al., 1991b), CD44 has been shown to 
undergo a sequential proteolytic cleavage in which an extracellular fragment is released 
to the serum or synovial fluid in the form of a soluble CD44.  Some studies have shown 
that the released soluble CD44 competes with binding of endogenous full length CD44 
to HA and thus, accentuates the loss of cell-matrix interactions further altering tissue 
homeostasis.  In addition, as a result of the sequential cleavage, an intracellular 
fragment is released (CD44-ICD), but the specific effects of this peptide remain unclear.   
 
Recently, our laboratory has demonstrated that human osteoarthritic 
chondrocytes in culture exhibit significant cleavage of CD44 (Takeda et al., 2010). This 
cleavage results in the generation of an 18-20 kD C-terminal fragment of CD44 (CD44-
EXT) as well as a 15 kD CD44-ICD.   The general MMP inhibitor, GM6001, blocked 
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generation of the CD44-EXT and, generation of the CD44-ICD was blocked by the γ-
secretase inhibitor, DAPT.   Normal bovine chondrocytes exhibited little CD44 
degradation but the cleavage can be induced by experimental conditions that mimic OA.   
Although we demonstrated that CD44 proteolysis in chondrocytes occurs, the biological 
consequences of this proteolytic process remains unknown, especially in articular 
chondrocytes.   This study attempts to understand the significance of CD44 proteolytic 
cleavage in articular cartilage/chondrocytes and the potential implications of these 
changes during the development of OA. 
 
We hypothesize that a CD44-ICD released into the cytoplasm of chondrocytes 
will function as a dominant negative competitor of CD44-FL; interfering with interactions 
between CD44-FL and its intracellular binding partners.   If correct, the over-expression 
of CD44-ICD would also serve as an experimental probe to validate interactions 
between CD44-FL and putative intracellular binding partners. 
 
 
1. Determine the biological consequences of intracellular  
CD44-ICD accumulation within chondrocytes. 
 
1.1. Development of molecular probes and model systems.   
The main focus of this study is to address the effects of CD44-ICD over-
expression in chondrocytes, and determine any biological interactions it may have with 
the endogenous CD44-FL.  In order to achieve this goal, many CD44-ICD, CD44-FL 
and Smad1 constructs were designed, including some with epitope tags at the C-
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terminus (CD44-ICD-myc, CD44-ICD-EGFP, CD44-FL-EGFP, Smad1-EGFP), others 
with tags at the N-terminus (GFP-CD44-ICD, GFP-Smad1, RFP-CD44-ICD), and also 
an untagged CD44-ICD to ensure that the epitope tag did not have an effect on CD44-
ICD behavior (Figure 4).   
 
1.1.1. Development of different recombinant CD44-ICD expressing plasmids.   
To generate the untagged CD44-ICD and CD44-ICD-myc, primers were 
designed to amplify the CD44-ICD sequence from a full-length pCDM8-CD44H.  The 
PCR amplified product was immediately subcloned into a TOPO TA vector, which 
allows easy ligation using a topoisomerase, I enzyme covalently bound directly to the 
plasmid.  The topoisomerase I enzyme adds an additional adenine (A) to the end of 
each DNA strand, allowing easy ligation into a vector containing complimentary 
overhanging thymidine (T).  The only problem with this fast TOPO TA ligation system, is 
that the insert can be cloned in either the 5'→3' or 3'→5' direction.  A restriction digest 
with Pvu II restriction enzyme, which cuts 3 times within the vector and once within the 
ICD insert allowed us to determine cloning directionality by comparing band sizes.  
Products inserted in the forward direct were expected to exhibit 472, 1071, 1097 and 
3119 bp restriction bands whereas products inserted in the reverse direction expected 
586, 1071, 1097 and 3005 bands (Figure 8).  Three forward and one reverse inserts 
were detected; the strongest forward clone was used for further subcloning.   Samples 
were also sent to the Genomics Core Facility of East Carolina University for DNA 
sequencing to verify results from the restriction digest. 
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Once a properly cloned TOPO-CD44-ICD was identified, the CD44-ICD insert 
was released by double sequential digest using Sal I and Not I restriction enzymes and 
Figure 8:  Restriction digest of CD44-ICD with Pvu II to determine cloning 
directionality in TOPO TA vectors.  A. Predicted restriction map of Pvu II sites of 
pcDNA3.1/V5-His-TOPO-CD44-ICD if cloned in the 5'→3' direction (left) or in the 3'→5' 
direction (right).  B. Tab e estimating the band sizes (bp) b twe n Pvu II sites for cloning 
in both directions, and 1% agarose gel showing the restriction digest with Pvu II for 4 
different clones.  Only the second p nel has a lar er size band of 586 bp, m aning that 
the CD44-ICD was cloned in the 3'→5' direction, while the other 3 clones were correctly 
cloned in the 5'→3' direction.  Sequencing results confirmed these data (not shown). 
 
 
 
 
 
 
 
A. 
B. 
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directionally inserted into an open pCMV/myc/cyto vector. Once the plasmid DNA was 
purified, cloning was verified by a double sequential restriction digest with the same 
enzymes, Sal I and Not I, which yielded a ~233 bp band (Figure 9).   CD44-ICD protein 
expression was verified by western blotting of lysates of transiently transfected COS-7 
cells with CD44 bands detected using the anti-CD44-cytotail antibody.   As shown in 
Figure 10, a ~15 kD band was detected in cells transfected with untagged CD44-ICD 
plasmid, and an ~16 kD band in pCMV/myc/cyto plasmids containing the CD44-ICD-
myc (not shown).  As a control, cells were transfected with an empty pCMV/myc/cyto 
vector or non-transfected, and no bands were detected in this range. Correct insertion 
of CD44-ICD into pCMV/myc/cyto plasmids was also verified by DNA sequencing of the 
plasmids by the Genomics Core Facility of East Carolina University. 
 
Successful cloning of the untagged CD44-ICD and CD44-ICD-myc into the 
pCMV/myc/cyto vector provided the necessary start codons and Kozak sequence 
necessary for expression of this domain in eukaryotic cells.   From this point, the CD44-
ICD, together with the pCMV/myc/cyto translational start sequence could be subcloned 
into additional plasmid vectors (pEGFP-N2 and pcDNA5.1FRT).    New primers were 
designed to amplify the untagged CD44-ICD including the start site from the 
pCMV/myc/cyto vector and the natural stop of the CD44-ICD sequence.    These 
primers also included a Hind III and Apa I restriction sites to cut the CD44-ICD product 
after subcloning into a TOPO TA vector.  The PCR amplified product was subcloned 
into a TOPO TA vector, and cloning directionality was tested once again with a single 
restriction digest using the Pvu II restriction enzyme.   After verifying cloning  
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Figure 9:  Agarose gel of a sequential double restriction digest with Sal I and Not I 
to verify successful cloning of CD44-ICD insert into pCMV/myc/cyto vector.  Three 
clones were selected and purified, and a double restriction digest with Sal I and Not I 
restriction enzymes was performed to determine insertion of the CD44-ICD into the empty 
pCMV/myc/cyto vector.  All three clones had an insert of ~233 bp.  As a control, an 
aliquot of the PCR reaction used to amplify the CD44-ICD from the pCDM8-CD44H 
plasmid was run next to the restriction digests to verify that the size of the digested insert 
was equivalent to that of the PCR product. 
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Figure 10:  Western blot of COS-7 cells transiently transfected with 
pCMV/myc/cyto-CD44-ICD plasmid.  COS-7 cells were either non-transfected (control) 
or transfected with untagged CD44-ICD.  Cell lysates were analyzed by western blotting 
using anti-CD44-cytotail antibody.  Protein detection with CD44-cytotail antibody shows a 
band at 15 kD consistent with the size of the untagged CD44-ICD 
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directionality, a double digest using Hind III and Apa I restriction enzymes was 
performed to cut the CD44-ICD insert from the TOPO vector followed by insertion into 
an open pEGFP-N2 plasmid.  Cloning into the pEGFP-N2 was verified by a double 
digest with Hind III and Apa I restriction enzymes.  CD44-ICD-EGFP fusion protein 
expression was also verified by western blotting of lysates of transiently transfected 
COS-7 cells, with CD44-ICD-EGFP bands detected using the anti-GFP antibody and 
anti-CD44-cytotail antibody.  As shown in Figure 11, a ~45 kD band was detected in 
cells transfected with CD44-ICD-EGFP plasmid.   Correct insertion of CD44-ICD into 
pEGFP-N2 plasmid was also verified by DNA sequencing of the plasmids by the 
Genomics Core Facility of East Carolina University. 
 
To ensure that the position of such a large epitope tag on the C-terminal of 
CD44-ICD (the size of EGFP is ~30 kD) did not have an effect on CD44-ICD function, 
another CD44-ICD construct was designed with an N-terminal GFP tag.  The same 
primers used for subcloning the untagged-CD44-ICD into the pCMV/myc/cyto plasmid 
were used to PCR amplify the CD44-ICD sequence from the original full-length pCDM8-
CD44H plasmid.  The PCR product was directly cloned into a GFP-TOPO TA vector 
such that the GFP and CD44-ICD were in-frame at the 5ʹ′ end of the insert.  Cloning 
directionality was verified by Pvu II restriction digest and sequencing of the plasmid by 
the Genomics Core Facility of East Carolina University. 
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Figure 11:  Western blot of COS-7 cells transiently transfected with GFP-CD44-ICD 
or CD44-ICD-EGFP plasmids.  COS-7 cells were either non-transfected (control) or 
transfected with GFP-CD44-ICD or CD44-ICD-EGFP.  Protein detection with an anti-GFP 
antibody and anti-CD44-cytotail antibody shows a band at ~45kD correspondent to the 
size of the CD44-ICD fusion proteins with GFP or EGFP tags. 
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The GFP-TOPO TA plasmid contains a promoter and start sequence to drive 
expression of the GFP protein and its fusion protein partner, the CD44-ICD.   Protein  
expression was verified by western blotting of lysates from transiently transfected COS-
7 cells with GFP-containing protein bands detected using the anti-GFP antibody and the 
anti-CD44-cytotail antibody .  As shown in Figure 11, a ~45 kD band was detected in 
cells transfected with pGFP-CD44-ICD plasmid, similar in size to CD44-ICD-EGFP 
lysates. 
 
Lastly, a CD44-ICD with an N-terminal Red Fusion Protein (RFP) tag was 
subcloned in order to use a different fluorescent color in co-transfection with other GFP 
constructs. The GFP-CD44-ICD construct was digested using Hind III and Apa I 
restriction enzymes and directly subcloned into an open pDsRed2-C1 vector.  Protein 
expression was not detected with the CD44-cytotail antibody, and sequencing results 
confirmed that CD44-ICD was not in-frame with RFP.  Cloning was repeated with a 
different set of primers and we were still unable to perform in-frame cloning. 
  
1.1.2. Development of a recombinant control non-relevant peptide expressing plasmids. 
To demonstrate specificity of CD44-ICD throughout this study, a “non-relevant” 
control expression peptide was developed using the Gene-Taylor Site-Directed 
Mutagenesis™ kit from Invitrogen.  Primers were designed to add a single base pair at 
the beginning of the sequence, shifting the entire reading frame and thus translating a 
~15 kD peptide with a different sequence than that of CD44-ICD.  No premature stops 
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were introduced as a result of this frame shift, with the exception of one that was 
located only few bases before the natural stop codon. 
 
We had no available antibody to detect the non-relevant peptide as the CD44-
cytotail antibody would not recognize the new sequence.  A restriction digest with Sal I 
and Not I restriction enzymes verified the presence of a ~233 bp insert (Figure 12), 
however the only way to truly identify if the point mutation was incorporated was by 
sequencing the DNA. This peptide was used as a control in several transfection 
experiments to determine whether the effects of CD44-ICD were specific. 
 
1.1.3. Development of Smad1 expressing plasmids. 
Smad1 has been shown to interact with the intracellular domain of CD44 by a 
yeast-two hybrid screen and co-immunoprecipitation studies (Peterson et al., 2004). 
Smad1 is a member of the bone morphogenetic protein (BMP) signaling pathway.   
Upon activation via a BMP such as BMP 7, Smad1becomes phosphorylated and 
dissociates from the BMP receptor and presumably, the cell surface receptor CD44.  
Phospho-Smad1 then translocates to the nucleus.  The purpose of creating green 
fluorescent Smad1 fusion proteins was to visualize Smad1 translocation to the nucleus 
following BMP 7 activation, and to explore whether CD44-ICD could bind to Smad1 
and/or affect endogenous CD44-Smad1 interactions. 
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Figure 12:  Agarose gel of a double sequential restriction digest with Sal I and Not I 
restriction enzymes to verify cloning of non-relevant peptide into pCMV/myc/cyto 
vector.  A single point mutation was introduced into the pCMV/myc/cyto/CD44-ICD 
(untagged ICD) sequence to create a non-relevant peptide similar in size to CD44-ICD.  A 
double restriction digest (lane R.D.) with Sal I and Not I restriction enzymes was 
performed to verify that the ~233 bp insert was cloned into the pCMV/myc/cyto vector.  
pCMV/myc/cyto/CD44-ICD (Untagged CD44-ICD) was used as a control. 
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 Two Smad1 constructs were generated, one with an N-terminal GFP tag and one 
with a C-terminal EGFP tag to ensure that the location of the epitope tag did not 
influence Smad1 behavior.   
 
First, a previously cloned Smad1 into a pcDNA 3.1/myc-His A construct was 
digested using Hind III and Apa I restriction enzymes to remove the ~1,400 bp Smad1 
insert that was then subcloned into an open pEGFP-N2 vector to create the Smad1-
EGFP fusion plasmid.  Cloning was verified by a double restriction digest of Smad1-
EGFP using the Hind III and Apa I restriction enzymes to ensure the 1,400 bp Smad1 
insert was properly cloned (Figure 13), by protein expression of a 90 kD fusion protein 
(i.e. Smad = 60 kD and EGFP = 30 kD) by western blotting using Smad1 and GFP 
antibodies (Figure 14), and DNA sequencing. 
 
Next, to generate a Smad1 fusion protein with a GFP tag on the N-terminus, 
primers were designed to PCR-amplify Smad1 from a previously cloned Smad1 present 
in a pcDNA 3.1/myc-His A plasmid.  The PCR amplified product was sublconed into a 
pcDNA3.1/NT-GFP-TOPO vector to produce a GFP-Smad1 construct.  Cloning was 
verified by double restriction digest with Hind III and Apa I which yields a ~1,400 bp 
(Figure 13), protein detection by western blotting using a GFP or Smad1 antibodies, and 
DNA sequencing. 
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Figure 13:  Agarose gel of a double restriction digest with Hind III and Apa I 
restriction enzymes to verify cloning of Smad1.  Smad1 was cloned into a 
pcDNA3.1/NT-GFP-TOPO vector to produce a GFP-Smad1 construct, and into a pEGFP-
N2 vector to generate the Smad1-EGFP fusion plasmid.  Cloning was verified by a 
double restriction digest using Hind III and Apa I restriction enzymes to release the 
Smad1 insert (~1,400 bp) from the plasmid. 
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Figure 14:  Western blot of COS-7 cells transiently transfected with EGFP or 
Smad1-EGFP.  Protein expression of Smad1-EGFP fusion protein was detected at ~90 
kD using an anti-GFP and an anti-Smad1 antibody.  In addition, endogenous Smad1 
expression was detected at ~60 kD using the anti-Smad1 antibody.  Expression of free 
EGFP was detected using the anti-GFP antibody at ~30 kD. 
 
 
 
 
 
 
 
 
 
Figure 14:  Western blot of COS-7 cells transiently transfected with EGFP or 
Smad1-EGFP.  Protein expression of Smad1-EGFP fusion protein was detected at ~90 
kD using an anti-GFP and an anti-Smad1 antibody.  In addition, endogenous Smad1 
expression was detected at ~60 kD using the anti-Smad1 antibody.  Expression of free 
EGFP was detected using the anti-GFP antibody at ~30 kD. 
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1.1.4. Development of stable transfectants of CD44-ICD. 
Using the Flp-In™ system from Invitrogen, two stable CD44-ICD transfectant cell 
lines were generated: HEK-293-CD44-ICD and RCS-CD44-ICD.  Western blot analysis 
shows high CD44-ICD protein expression in both cell lines, when compared to the 
parental cells (Figure 15-16).  In addition, it appears that endogenous CD44 expression 
is increased in the stable cell lines, possibly indicating that CD44-ICD does translocate 
to the nucleus and activates transcription of different genes, including CD44 itself, as 
reported by others (Nagano and Saya, 2004).  The CD44-ICD stable chondrocyte cell 
line RCS was a useful tool to study CD44-ICD over-expression.  
 
1.2. Cellular effects that occur following the introduction/over-expression of a 
rhCD44-ICD. 
The effects of CD44-ICD over-expression on several cellular functions known or 
proposed to be dependent on CD44-FL were investigated.  These included effects on 
CD44-FL proteolysis, effects on Smad1 nuclear translocation, and effects on matrix 
retention and binding to the actin cytoskeleton. 
 
During the cleavage of CD44-FL by metalloproteinases and γ-secretase, 
accumulation of intracellular CD44-ICD is one expected result.  As such, accumulation 
of CD44-ICD may exert a negative-feedback effect on further CD44-FL cleavage.  To 
explore this possibility, over-expression of rhCD44-ICD was examined in a model cell 
system in which CD44-FL was naturally expressed (RCS, HEK-293), or co-transfected 
with pCD44-FL if the cell line lacked endogenous CD44-FL expression (COS-7).  
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In both stable CD44-ICD model systems (i.e. RCS and HEK-293), CD44-FL 
expression was compared in parental and stable CD44-ICD transfectant cells. HEK-293 
parental cells expressed very little endogenous CD44-FL, and over-expression of 
CD44-ICD did not induce proteolytic cleavage of CD44-FL (Figure 15).  RCS cells have 
higher expression of endogenous CD44-FL, and similar to HEK-293-CD44-ICD 
transfectants, RCS-CD44-ICD stable transfectants did not induce or inhibit 
fragmentation of the endogenous CD44-FL (Figure 16). 
 
In a transient transfection system in COS-7 cells, pCDM8-CD44H was co-
transfected either with empty GFP vector (control) or with GFP-CD44-ICD to examine 
effects of CD44-ICD on exogenous CD44-FL proteolysis.   As shown in figure 17, under 
these conditions, CD44-FL was observed as a ~85 kD protein.   In addition an 18-20 kD 
band indicative of CD44-EXT was again observed.  Following pre-incubation with both 
GM6001 and DAPT inhibitors, generation of the 18-20 kD CD44-EXT band was reduced 
in both transfections.  In addition, co-transfection with CD44-FL and GFP-CD44-ICD, 
showed a clearly defined band for GFP-CD44-ICD at 45 kD.  However, over-expression 
of CD44-ICD did not appear to further induce or to inhibit CD44-FL proteolysis (Figure 
17, lane 1 and 3).   
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Figure 15:  CD44 expression in parental HEK-293 and HEK-293-CD44-ICD stable 
transfectants.  Protein expression of CD44-FL (~85 kD) and CD44-ICD (15 kD) was 
detected in lysates of HEK-293 parental cells and HEK-293-CD44-ICD stable 
transfectants by western blotting using CD44-cytotail antibody. 
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Figure 16:  CD44 expression in parental RCS and RCS-CD44-ICD stable 
transfectants.  Protein expression of CD44-FL (~70 kD) and CD44-ICD (15 
kD) was detected in lysates of RCS parental cells and RCS-CD44-ICD stable 
transfectants by western blotting using CD44-cytotail antibody. 
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Figure 17:  Effect of CD44-ICD over-expression on CD44-FL fragmentation in COS-7 
cells.  COS-7 cells were co-transfected with empty EGFP-N2 plasmid (as a transfection 
efficiency marker) and pCD44-FL or pGFP-CD44-ICD and pCD44-FL.  Following 
transfection, the cells were treated with or without a combination of protease inhibitors, 
GM6001 and DAPT.    Protein expression of CD44-FL (~85 kD), GFP-CD44-ICD (~45 
kD) and, CD44-EXT (18-20 kD) were detected in lysates of transiently transfected COS-7 
cells by western blotting using anti-CD44-cytotail antibody.  In both co-transfections 
CD44-EXT fragments (indicative of CD44-FL fragmentation) were reduced in the 
presence of protease inhibitors.  GFP-CD44-ICD over-expression had a only a minor 
effect on reducing CD44-FL fragmentation (lane 3 compared to lane 1; lane 4 compared 
to lane 2. 
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These results suggest that, at least in the model system, over-expression of 
CD44-ICD exerts little negative-feedback effects on subsequent CD44 cleavage activity. 
 
CD44-FL as the receptor alone (pCDM8-CD44H) or as a fusion protein with 
EGFP (CD44-FL-EGFP) was transfected into a variety of cell types.   As shown in 
Figure 18 transient transfection into COS-7 cells, C28/I2 cells and bovine articular 
chondrocytes was achieved.  However, for subsequent western blot analyses, 
transfection into COS-7 cells was used as these cells had the highest transfection 
efficiency.   It should be noted however, that under these non-activated control 
conditions, little EGFP appears in the nucleus of these cells.    
 
On western blots, CD44-FL-EGFP expression in COS-7 cell lysates was 
observed using either anti-GFP antibody, an anti-CD44 cytotail antibody, as well as an 
anti-CD44 antibody (BU52) that recognized the N-terminal domain of CD44 (Figure 19).    
All three antibodies detected bands at the expected size of CD44-FL-EGFP (e.g., 85 kD 
+ 30 kD = 115 kD).   However, the anti-GFP and anti-cytotail antibodies, both of which 
recognize C-terminal domains, also detected additional lower molecular size bands of 
~45 kD.  This 45 kD band is indicative of CD44-ICD with the EGFP tag, the product of 
CD44 derived following the sequential metalloprotease and γ-secretase cleavage of 
CD44-FL.  The CD44-cytotail antibody also detected a non-specific band at ~75 kD.  
COS-7 cells are CD44-negative and therefore should not express endogenous CD44- 
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Figure 18:  Transient transfections of CD44-FL-EGFP plasmid in COS-7 and 
dBACs.  COS-7 cells (A and B) and dBACs (C and D) were nucleofected with CD44-
FL-EGFP plasmid, and 24 hours after transfection, protein expression was analyzed by 
fluorescent microscopy.  Merged images represent two-channel overlay images of 
green fluorescence and phase contrast images. 
 
 
 
 
 
A. B. 
C. D. 
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Figure 19: CD44-FL-EGFP fragmentation in COS-7 cells.  The CD44-FL-EGFP 
fusion protein expressed in transiently transfected or control (non-transfected) COS-7 
cells was detected using an anti-GFP, anti-CD44-cytotail and anti-CD44-ectodomain 
(BU52) antibodies.  All three antibodies detected the CD44-FL-EGFP fusion protein at 
the expected size of ~115 kD.  In addition, a ~45 kD fragment was also detected with 
the blots were probed using either the anti- GFP or the anti-CD44-cytotail antibodies.   
The presence of a 45 kD fragment is indicative of proteolytic fragmentation of CD44-FL-
EGFP into CD44-EXT-EGFP or CD44-ICD-EGFP peptides. A non-specific band was 
also detected at~75 kD using the anti-CD44-cytotail antibody. This is not endogenous 
CD44-FL as COS-7 cells are CD44 negative, and BU52 antibody did not detect the 
same band. 
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FL.  If this “non-specific” band was CD44-FL, it should also be recognized by the BU52 
antibody, and as seen in Figure 19, BU52 only recognized CD44-FL-EGFP fusion 
proteins. 
 
  When the lysate from the transient transfection of COS-7 cells with CD44-FL-
EGFP was loaded into lane adjacent to COS-7 transfected with GFP-CD44-ICD lysates, 
the fragmented band that resulted from the CD44-FL-EGFP transfection was of 
equivalent size to that of GFP-CD44-ICD transfection (Figure 20).  This suggests that 
CD44-FL-EGFP undergoes proteolysis in COS-7 cells resulting in the generation of a 
CD44-ICD-EGFP. 
 
1.2.2. Effect of CD44-ICD on activation of Smad1  
BMP 7 is a member of the TGF-β superfamily, which binds to type I and type II 
receptors. Ligand binding induces phosphorylation of the receptors, which in turn 
activate R-Smads (Smad 1, 5 and 8) presented by transmembrane proteins such as 
CD44.  The R-Smad dissociates from its receptor and binds to a Co-Smad (Smad 4) to 
form a Smad complex.  The Smad complex translocates into the nucleus and regulates 
expression of target genes. 
 
It is still unknown whether cleaved CD44-ICD can interact with Smad1 and 
translocate to the nucleus, or whether it blocks endogenous CD44-FL binding to Smad1  
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Figure 20:  CD44-FL-EGFP fragments that accumulate in transfected COS-7 cells 
match the size of the GFP-CD44-ICD peptide.  Western blot of lysates from COS-7 
cells transiently transfected with either GFP-CD44-ICD plasmid (~45 kD) or CD44-FL-
EGFP (~115 kD) were detected using an anti-GFP antibody.  The CD44-FL-EGFP 
transfectants not only show expression of the full-length CD44-EGFP, but also a 
fragment at ~ 45 kD that is similar in size to GFP-CD44-ICD. 
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by sequestering Smad1 and thus interfering with the BMP 7/Smad1 signaling pathway.   
Therefore, our goal in this section was to determine if CD44-ICD over-expression 
affected the CD44/Smad1 signaling pathway. 
 
1.2.2.1. Effects on Smad1 cellular localization 
In the search for a good cell line model responsive to BMP 7 activation, several 
cell lines were transfected with Smad1-EGFP and treated with BMP 7. C28/I2 cells were 
the only cells that exhibited, albeit limited, translocation of the Smad1-EGFP fusion 
protein to the nucleus after BMP 7 activation.   
 
For these studies, C28/I2 cells were transfected with Smad1-EGFP and plated in 
a chamber slide.  After 48 hours of transfection, the cells were incubated first for 30 
minutes in serum free DMEM and then treated with BMP 7 for 1 hour (control cells were 
left in serum free DMEM).  In control C28/I2 cells without BMP 7 treatment, Smad1-
EGFP displayed mainly a cytoplasmic localization (Figure 21 A-B).   In response to 1 
hour BMP 7 treatment in live cells, enhanced nuclear concentration of the Smad1-EGFP 
fusion protein was observed (Figure 21 C-D), indicative of Smad1-EGFP nuclear 
translocation. 
 
De-differentiated bovine articular chondrocytes (dBACs) were cultured in 
monolayer for three passages.  dBACs allow for a higher transfection efficiency than 
primary chondrocytes (BACs).   The dBACs were transfected with empty EGFP vector  
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Figure 21: Smad1-EGFP translocation in response to BMP 7 treatment in the 
immortalized human chondrocyte cell line, C28/I2.  Panels A and B, C28/I2 cells 
incubated in serum-free media; panels C and D, C28/I2 cells incubated in serum-free 
media containing 100 ng/ml BMP 7 for 1hr.   Smad1-EGFP and DAPI nuclear staining 
(blue fluorescence) are shown separately.  Control C28/I2 cells display a cytoplasmic 
localization of the Smad1-EGFP fusion protein.  After cells were treated with BMP 7 for 
1hr, nuclear translocation was observed in some of the successfully transfected cells.    
 
 
 
 
 
A. B. 
C. D. 
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or the Smad1-EGFP expression vector to determine cellular localization of each protein 
(Figure 22).  Free EGFP showed both nuclear and cytoplasmic localization (Figure 22 
A-B) while the Smad1-EGFP expression was predominantly cytoplasmic (Figure 22 C-
D).   These results suggest that EGFP domain does not influence the cytoplasmic 
localization of the Smad1-EGFP fusion protein.       
 
When dBACs were transfected with Smad1-EGFP and then treated with BMP 7, 
no nuclear translocation was observed.  The lack of a nuclear translocation response is 
likely complex and may have included a diminished responsiveness of the dBACs to 
BMP 7 as well as other morphological and biological changes that occur as these cells 
begin to de-differentiate.   At this early stage of my studies, given that primary BACs 
were difficult to transfect with high efficiency and dBACs exhibited limited 
responsiveness to BMP 7, examining the potential effects of CD44-ICD over-expression 
on Smad1 localization in chondrocytes was not pursued further.  
 
1.2.2.2. Effects on Smad1 phosphorylation 
 
  Smad1 binds to the intracellular domain of CD44-FL.  Upon BMP 7 activation, 
Smad1 gets phosphorylated and dissociates from the receptor.  Phosphorylated Smad1 
then forms a complex with a Smad 4, and together as a complex, this Smad protein 
complex translocates to the nucleus and activates transcription of target genes.  As 
such, measuring phosphorylation of Smad1 (pSmad1) levels in a model system, is one 
way to examine activation of the CD44/Smad1 signaling pathway. 
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Figure 22: Smad1-EGFP translocation in dBACs.  Localization of free EGFP derived 
from the empty EGFP-N2 vector is both cytoplasmic and nuclear in dBACs (panels A 
and B).    Smad1-EGFP was primarily cytoplasmic (panels C and D) in resting dBACs.   
These results imply that the EGFP tag does not influence Smad1-EGFP localization.   
Right panels (B and D) depict two-color overlay images of green (EGFP) and blue 
fluorescence (DAPI).   
 
 
 
 
  
 
 
A. B. 
C. D. 
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To investigate the effects of CD44-ICD over-expression on CD44/Smad1 
interactions, cell lysates of parental RCS and RCS-CD44-ICD stable transfectants were 
prepared and Smad1 phosphorylation levels examined using a phosphorylation specific 
antibody.  As shown in figure 23, basal levels of pSmad1 were lower in lysates of stable 
CD44-ICD transfectants as compared to control, parental cells.  In addition, when RCS-
CD44-ICD transfectants were treated for 1 hour with BMP 7, the cells did not seem to 
exhibit a strong pSmad1 response to the ligand activation as compared to the RCS 
parental cell line (Figure 23B). 
 
 
1.2.3. Changes in CD44-ICD generated from CD44-FL-EGFP degradation 
 Data shown in Figure 20 demonstrated that CD44-FL-EGFP expressed in 
transiently transfected COS-7 cells underwent proteolytic cleavage resulting in the 
generation of a CD44-ICD-EGFP.    Fluorescence microscopy was then used to 
visualize whether any of this newly generated CD44-ICD-EGFP translocated into the 
nucleus.   If nuclear accumulation was observed, we could then determine whether 
blocking the fragmentation by adding the general MMP inhibitor GM6001 and γ-
secretase inhibitor DAPT inhibitors, blocked this accumulation. 
   
    Twenty-four hours after transfection, the COS-7 cells were treated overnight with a 
combination of GM6001 and DAPT inhibitors, or left untreated in DMEM media 
containing 10%FBS.    In control non-treated cells, the EGFP fluorescent tag was 
localized not only along the plasma membrane but also within the nucleus (Figure 24A).   
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Figure 23:  Effects of CD44-ICD on Smad1 phosphorylation.  A. Shown are basal 
levels of pSmad1 present in direct lysates of RCS parental and RCS-CD44-ICD 
transfectants.    The basal level of pSmad appears to be down-regulated in RCS-CD44-
ICD transfectants as compared to RCS parental cell lines.  β-actin was used to verify that 
equal protein was loaded.  B. Lysates of RCS parental and RCS-CD44-ICD transfectants    
following activation with BMP 7.  Parental RCS cells responded to BMP 7 activation by 
having up-regulation of pSmad.  However, stable RCS-CD44-ICD transfectants did not 
appear to be responsive to BMP 7 activation signaling. 
A. B. 
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Figure 24: Transient transfection of COS-7 cells with pCD44-FL-EGFP treated with 
and without GM6001 and DAPT inhibitors.  COS-7 cells were transfected with 
pCD44-FL-EGFP.  Following transfection, the cells were treated without (A) or with (B) a 
combination of protease inhibitors, GM6001 and DAPT.    
 
 
 
 
 
A. 
B. 
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On the other hand, in cells treated with both metalloproteinase and γ-secretase 
inhibitors, the nuclear accumulation of EGFP was not observed (Figure 24B).  These 
results are consistent with our hypothesis that the nuclear EGFP observed in control 
cells represented CD44-ICD-EGFP fragments that had translocated into the nucleus. 
 
1.2.4. Effect of CD44-ICD on chondrocyte capacity to retain a pericellular matrix. 
CD44 acts as a mediator between individual chondrocytes and the extracellular 
matrix to fine tune cellular responses to cytokines and growth factors.   The extracellular 
domain of CD44 binds to the HA/proteoglycan rich extracellular matrix, which can be 
visualized by several assays such as particle exclusion assay or specific staining of HA 
using a biotinylated HA binding protein (HABP) probe. 
 
Our goal was to use these two assays to determine if CD44-ICD over-expression 
had an effect on CD44-FL ability to retain a pericellular matrix (also called a pericellular 
“coat”).  We hypothesized that CD44-ICD would have a dominant-negative effect on 
CD44-FL, competing with CD44-FL binding to the cytoskeleton.   Similar to disruption of 
the cytoskeleton with cytochalasin or latrunculin, a loss of interaction with the 
cytoskeleton would result results in a loss of the pericellular coat (Nofal and Knudson, 
2002).  This implies that CD44-ICD would affect inside-out functions of CD44-FL, 
namely the critical function of maintaining chondrocyte/matrix interactions. 
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1.2.4.1. Observation of pericellular matrix loss by particle exclusion assay. 
The first approach to study the effects of CD44-ICD over-expression on endogenous 
CD44-FL-mediated coat retention was to do a particle exclusion assay on transfected or 
control chondrocytes.  CD44-ICD constructs including a GFP tag were often used to 
distinguish transfected cells (green fluorescence) from non-transfected cells (non-
fluorescent) within the same culture.   Matrix retention was also examined using 
chondrocytes transfected with an empty GFP vector to ensure that the GFP tag had no 
effect on coat retention.  Forty eight hours after transfection, a suspension of exclusion 
particles (fixed red blood cells) was applied to the cultures and living cells were 
observed using inverted fluorescence as well as inverted phase contrast microscopy.  
 
 Transient co-transfections of BACs with a CD44-ICD-myc construct, together 
with an EGFP marker plasmid, resulted in a reduction of the pericellular coat when 
compared to the non-transfected chondrocytes.   One example is shown in Figure 25.  
The control cell (GFP-negative) exhibited a prominent pericellular coat whereas the 
GFP-positive cells displayed little or no coat.  No coat was defined as particles coming 
to settle directly adjacent to the cell plasma membrane, resulting in no exclusion zone.   
Another example of a particle exclusion assay of RCS cells transiently transfected with 
CD44-ICD-EGFP is shown in Figure 26.  Again, most of the transfected cells were 
devoid of coats. However, occasionally some transfected cells would have a pericellular 
coat and, some non-transfectants would not exhibit a coat.    
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Figure 25. Effect of CD44-ICD over-expression in bovine articular chondrocytes 
on pericellular coats.  BACs were co-transfected with empty GFP vector and CD44-
ICD-myc. Successfully transfected BAC are GFP-positive and express the CD44-ICD; 
non-transfected cells within the same field are GFP-negative and serve as controls.  
GFP-negative cell (yellow arrow) displays a pericellular coat (particle exclusion zone 
due to the presence of cell-bound extracellular matrix). The GFP-positive cells exhibit a 
reduced pericellular coat. 
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Figure 26: Effect of CD44-ICD over-expression on pericellular coats in transiently 
transfected RCS cells.  Panels A and B depict overlay images of two representative 
fields of view of RCS cells transiently transfected with CD44-ICD-EGFP.  Two days 
following transfection the cells were analyzed by the particle exclusion assay.   Most of 
the CD44-ICD-EGFP positive cells (green fluorescence) had no pericellular matrix 
(coat).  However, some non-transfected control cells also appeared to have no coat.  
Panel C is a numerical count of transfected versus non-transfected cells with or without 
a coat; panel D is a graphic depiction of the same data, with the total number of cells 
counted on the y-axis.   Data represents a total of 223 cells counted, taken from one 
pilot experiment. 
 
 
 
A. B. 
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D. 
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In order to account for this variability, images were prepared from several fields of view, 
taken from the same transfection. Each cell was placed in one of four categories:  Non-
transfected with coat, non-transfected without coat, transfected with coat and 
transfected without coat.  Out of a total of 223 cells, 44 cells were transfected and 42 of 
the transfected cell did not retain a coat (98% of transfected cell had no coat).  Out of 
the 179 non-transfected cells, 58 cells had a coat (33% of non-transfected cells had a 
coat) (Figure 26C and D).  These results were duplicated with similar results.   Although 
convincing, I continued to optimize conditions to improve on this approach.  The particle 
exclusion assay was optimized for use on RCS cells.   Together with careful control of 
RCS growth in culture, fewer control RCS cells displayed without coats.   Secondly, 
stable CD44-ICD transfectants of RCS cells were developed. 
  
As shown in Figure 27A, prominent coats are observed on cells of the parental RCS 
cell line.  In these studies the cells were treated with calcein-AM (Invitrogen) prior to 
coat analysis to provide contrast and delineate the extent of the plasma membrane.  
Calcein-AM is a hydrophobic compound that permeates into live, intact cells, becomes 
cleaved intracellularly releasing a strong fluorescent signal (Figure 27).   In contrast, all 
of the stable RCS-CD44-ICD transfectants exhibited a complete reduction in the ability 
to retain a pericellular coat.  
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Figure 27:  Effect of CD44-ICD over-expression on pericellular coats in stably 
transfected RCS cells.   Parental RCS cells (panel A) display intact pericellular coats as 
detected using the particle exclusion assay.  Stable hygromycin-resistant RCS-CD44-ICD 
transfectants (panel B) do not display pericellular coats.   Both panels depict two-color 
overlay of phase contrast and green fluorescence images.    Green fluorescence in both 
images is due to calcein-AM that stains live cells and was used to provide contrast.  
 
A. 
B. 
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Bovine articular chondrocytes (BACs) were treated with IL-1 or PMA to induce 
proteolytic cleavage of CD44-FL (Takahashi et al., 2010).  Twenty-four hours after 
treatment, calcein-AM was added to the cells to fluorescently stain the live cells shortly 
before adding the red blood cells for the particle exclusion assay.  Untreated 
chondrocytes display an intact pericellular coat, while cells treated with both IL-1 and 
PMA lost their pericellular coats (Figure 28). 
 
These data suggest that CD44-ICD over-expression has a dominant-negative effect 
on one of the most important functions of endogenous CD44-FL, namely the role of this 
matrix receptor to retain the pericellular coat in chondrocytes. 
 
1.2.4.2. Observation of pericellular matrix loss by immunostaining of hyaluronan. 
Another assay that allows visualization of CD44 ability to retain a pericellular coat 
is to directly visualize HA retained on chondrocytes through use of a biotinylated HABP 
probe.  No antibodies have been developed to recognize the polysaccharide HA.   
However, the HABP probe binds HA with high affinity and specificity similar to that of a 
conventional antibody.    In this assay, a chondrocyte that retains an intact coat is 
expected to exhibit a cortical staining of green fluorescence at the plasma membrane 
when incubated with neutravidin-FITC as a secondary reagent. 
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Figure 28:  Particle exclusion assay of BACs treated with agents that induce 
proteolytic cleavage of endogenous CD44-FL.   All panels depict two-color overlay of 
phase contrast and green fluorescence images.   Green fluorescence in all images is due 
to calcein-AM that stains live cells and was used to provide contrast.  All control, 
untreated BACs (panel A), display intact pericellular coats.   BACs treated with IL-1α 
(panel B) or PMA (panel C) exhibited nearly complete coat loss in all cells. 
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 Stable RCS-CD44-ICD transfectants were compared to the parental RCS using 
this assay.  Parental RCS chondrocytes exhibited a near-continuous staining of green 
fluorescence surrounding the entire plasma membranes of all cells.   This suggests that 
HA is retained along the perimeter of the cell, providing a stable pericellular coat around 
the cell (Figure 29A).  On the other hand, RCS-CD44-ICD stable transfectants did not 
show a continuous green staining along the entire plasma membrane (Figure 29B).    
There were scattered green patches in most of the cells.  These results indicate that 
one mechanism for retention of HA to the chondrocytes plasma membrane has been 
lost in the RCS-CD44-ICD stable transfectants.  Our hypothesis would predict that the 
fraction of HA not retained was the fraction dependent on binding to CD44-FL    What 
remains could represent HA that is being newly synthesized (HAS-bound HA) rather 
than CD44-bound HA.   Nonetheless, there was a clear difference between the two cell 
lines when compared side-to-side.   
 
2.  Determine the mechanism for CD44-ICD effects on cells 
2.1. Differential extractability of endogenous CD44-FL 
 Previous studies from our laboratory have demonstrated that membrane-
associated CD44 exists in two pools (Nofal & Knudson, 1999).  One pool can be readily 
extracted in a relatively low concentration of detergent (light condition) while another 
pool requires detergent conditions that disrupt not only membranes but protein-protein 
interactions as well (harsh condition).   Applying these two extraction approaches 
sequentially provided a method that we have termed differential extraction.  It was 
suggested that the CD44-FL pool released under harsh conditions represented  
  108 
 
 
 
 
 
 
 
 
 
 
Figure 29:  Changes in HA expression in parental RCS and RCS-CD44-ICD stable 
transfectants.   Depicted are two-color overlay images of parental RCS cells (panel A) or 
RCS-CD44-ICD stable transfectants (panel B) stained for HA using the biotinylated HABP 
probe (green fluorescence from neutravidin-FITC) and DAPI stain for nuclei (blue 
fluorescence).   Parental RCS cells display a continuous cortical ring of HA along their 
plasma membrane likely due to interactions between CD44 and HA.  However, RCS-
CD44-ICD stable transfectants (panel B) exhibit a disrupted pattern of cell surface HA.  
HA that is retained in the RCS-CD44-ICD cells may represent HA bound to HAS rather 
than HA bound to CD44. 
 
A. 
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receptors bound to the underlying actin cytoskeleton.  The light condition-extractable 
CD44-FL, represents the non-bound pool of free receptors (Nofal & Knudson, 1999).   
Differential extraction was used to study whether CD44-ICD exhibited a dominant-
negative effect on CD44-FL by competing with endogenous CD44 binding to the actin 
cytoskeleton.   
 
 First, to ensure that the effects of the light detergent has no effect on the actin 
cytoskeleton, C28/I2 chondrocytes in monolayer culture were pre-treated with no 
detergent (Figure 30A), light detergent [0.1% Igepal (aka NP-40)] (Figure 30B), or harsh 
detergent (0.5% Igepal containing 1% Empigen BB) (Figure 30C).  The actin 
cytoskeleton was stained with rhodamine-phalloidin after fixation and permeabilization.   
Filamentous actin can be detected under all conditions but the harsh detergent 
treatment does result in some disruption of the actin cytoskeleton.   
 
2.1.1. Changes in extractability due to conditions that promote CD44 fragmentation. 
Treating BACs with IL-1β or HA oligos (Takahashi et al., 2010) or PMA (Nagano 
et al., 2004) are conditions known to induce proteolytic cleavage of endogenous CD44-
FL.    This cleavage also results in the release of an endogenous pool of CD44-ICD.  
Previous data on coat retention of treated and untreated chondrocytes revealed that 
BACs treated with IL-1 or PMA resulted in coat reduction when compared to untreated 
cells (Figure 28). 
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Figure 30: Changes in the organization of the actin cytoskeleton following 
differential extraction of C28/I2 cells with light or harsh detergents.   C28/I2 cells 
were incubated without (panel A) or with light detergent (panel B) or, light detergent 
followed by harsh detergent (panel C).  Following incubations the cells were fixed, 
permeabilized and stained with RITC-phalloidin (red fluorescence) and DAPI stain for 
nuclei (blue fluorescence).  Two-color overlay of red and blue fluorescence images are 
shown. The light detergent did not affect a serious disruption of the actin cytoskeleton 
(panel B) and the cells appeared similar to untreated control cells (panel A).  The harsh 
detergent not only disrupted the cytoskeleton but also was associated with an 
enlargement of the nuclei, suggestive of cells undergoing cell death. 
 
A. 
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When investigating CD44 extractability in chondrocytes, untreated BACs had a 
higher percentage of the CD44-FL extracted with the harsh detergent as compared to  
the light extraction.   However, after treatment of BACs with IL-1β, HA oligos or PMA, a 
higher percentage of the CD44-FL was extracted using light conditions when compared 
to the pool of CD44 extracted under harsh conditions (Figure 31).   Interpretation of 
these results are complicated by the pleiotropic effects of IL-1β, HA oligos or PMA on 
BACs in addition to generating endogenous CD44-ICD. 
 
2.1.2. Changes in extractability due to over-expression of CD44-ICD. 
To test directly the effects of CD44-ICD on CD44-FL, we next explored whether 
over-expression of CD44-ICD affects endogenous CD44-FL/cytoskeleton interactions 
by using the differential extraction method.  BACs were transiently transfected with 
CD44-ICD-myc or GFP-CD44-ICD and compared to non-transfected chondrocytes.  
Both transfections resulted in a larger percentage of CD44-FL extracted with the light 
detergent when compared to the CD44-FL extracted with the harsh detergent (Figure 
32).  The non-transfected control chondrocytes again yielded a higher percentage of 
CD44 extracted with the harsh detergent.   
 
In a second set of experiments, stable RCS-CD44-ICD transfectants were 
compared to RCS parental cells.    A higher percentage of the CD44-FL was recovered 
under the light conditions in the RCS-CD44-ICD transfectants as compared to the harsh 
conditions (Figure 33).  Like the control BACs, a higher percentage of the CD44-FL was 
extracted with harsh conditions in the control, parental RCS cells.   
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Figure 31: Differential extraction of BACs treated with IL-1, HA oligos or PMA.   
High density monolayers of BACs were treated under a variety of conditions known to 
induce CD44 fragmentation and then detergent extracted using the sequential 
differential extraction approach.   Equal volume aliquots were analyzed by western 
blotting using the anti-CD44 cytotail antibody for detection.    In untreated cells (control) 
BACs, the majority of CD44-FL was extracted under harsh conditions, suggesting a 
strong interaction with the cytoskeleton.  However, in cells treated with IL-1, HA oligos 
or PMA, the majority of CD44-FL was extracted under light conditions, suggesting that 
the interaction between CD44-FL with the actin cytoskeleton was disrupted. 
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Figure 32: Differential extraction of BACs transiently transfected with CD44-ICD.   
Following nucleofection, BACs were allowed to recover as high density monolayer 
cultures for 2 days before preparation of cell lysates using the sequential differential 
extraction approach.   Equal volume aliquots were analyzed by western blotting using 
the anti-CD44 cytotail antibody for detection.    In non-transfected cells (control), the 
majority of CD44-FL was extracted under harsh conditions, suggesting a strong 
interaction with the cytoskeleton.  However, in cells transfected either with GFP-CD44-
ICD or with CD44-ICD-Myc, the majority of CD44-FL was extracted under light 
conditions, suggesting that a disruption of CD44-FL interaction with the actin 
cytoskeleton had occurred. 
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Figure 33:  Differential extraction of RCS parental and RCS-CD44-ICD stable 
transfectants.   High density monolayers of parental and CD44-ICD stable 
transfectants of RCS were extracted using the sequential differential extraction 
approach.   Equal volume aliquots were analyzed by western blotting using the anti-
CD44 cytotail antibody for detection.    In parental RCS cells, more CD44-FL was 
recovered following extraction under the harsh conditions than recovered using the light 
conditions.   In RCS-CD44-ICD stable transfectants, more of the CD44-FL was 
extracted under light conditions alone, suggesting a disruption in CD44-FL/cytoskeleton 
interactions. 
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Taken together, the data demonstrate that the extractability of the CD44-FL was 
altered in the presence of over-expressed CD44-ICD.  It was suggested previously 
(Nofal and Knudson, 2000) that this extractability was dependent on CD44-FL 
interaction with the actin cytoskeleton, suggesting that CD44-ICD may be a negative 
competitor to CD44-FL binding to the cytoskeleton.  Therefore, CD44-ICD effects on 
interactions between CD44-FL and cytoskeletal components were explored in more 
detail.   
 
2.2. Co-immunoprecipitation to study the effects on CD44-FL binding to the 
cytoskeleton 
Based on differential extraction data, it was hypothesized that CD44-ICD over-
expression had an effect on endogenous CD44-FL binding to the cytoskeleton.  To 
directly determine effects on these interactions, co-immunoprecipitation assays of 
CD44-FL with potential cytoskeletal binding proteins (e.g. ERM and Ankyrin) were 
developed. 
 
 There is conflicting evidence on how CD44 binds to the underlying actin 
cytoskeleton.  One group of data suggests that the cytoplasmic tail of CD44-FL binds to 
members of the ezrin/radixin/moesin (ERM) family of adaptor proteins (Duterme et al., 
2009; Hirao et al., 1996b; Tsukita et al., 1994). Other investigators have documented 
CD44 binding to the Ankyrin family of adaptor proteins (Lokeshwar et al., 1994; 
Singleton and Bourguignon, 2004). Either way, there is no direct evidence on how CD44 
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binds to the cytoskeleton in chondrocytes; therefore, both CD44/ERM and CD44/ankyrin 
interactions were evaluated in this study. 
 
2.2.1. Immunoprecipitation assays for CD44-FL 
After evaluating several approaches to immunoprecipitation assays, the 
Invitrogen dynabeads® approach proved the most successful.    Initial experiments 
were performed on RCS cell lysates, in which ~100 µg were incubated with the anti-
CD44 cytotail antibody.     To avoid problems due to immunoblotting with the same 
rabbit polyclonal, horseradish peroxidase (HRP) was directly conjugated to the anti-
CD44 antibody and used for detection.  As shown in Figure 34, the eluted fraction 
(antigens that bound to the beads) successfully pulled both CD44-FL and CD44-ICD, 
and the not-bound fraction had some CD44-FL, likely due to saturation of protein to the 
amount of antibody beads. 
 
2.2.2. CD44/ERM interactions 
Co-immunoprecipitation experiments were used to study potential interactions 
between CD44-FL and ERM proteins.   A recent study by Duterme and colleagues 
observed successful co-immunoprecipitation of CD44 with pERM in rat fibroblasts 
(Duterme et al., 2009).  Therefore, our initial experiments examined CD44/pERM co-
immunoprecipitations using their lysis buffer conditions.    
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Figure 34: Immunoprecipitation of CD44 in RCS cells.  RCS cell lysates were 
immunoprecipitated with the rabbit anti-CD44-cytotail antibody.   Equal volume aliquots 
of eluted and not-bound fractions were analyzed by western blotting using an HRP-
conjugated anti-CD44-cytotail antibody for immunodetection.  The eluted fraction 
(antibody-bound fraction) displays both CD44-FL and CD44-ICD.  Some CD44-FL was 
also detected in the not-bound fraction, possibly due to saturation of antibody-beads 
complex.    
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RCS were transiently transfected with CD44-ICD and treated with IL-1β.  These cells 
were compared to RCS transfected with the non-relevant peptide or non-transfected 
cells as controls.   First, the anti-CD44-cytotail antibody was used to pull down all CD44, 
and then probed with anti-pERM antibody (HRP-conjugated anti-pERM).   However, 
under these conditions, all pERM was detected in the not-bound fraction (Figure 35A).     
The same blots were then re-probed with anti-CD44-cytotail-HRP antibody.   CD44-FL 
and CD44-ICD were both successfully immunoprecipitated, and in fact, CD44-FL was in 
the antibody-retained fraction for all conditions (Figure 35B). 
 
 In a second series of experiments, possible co-immunoprecipitation of CD44 and 
pERM was compared between parental RCS and BAC to determine whether there was 
a difference between the two chondrocyte cell lines.   Again using anti-CD44-cytotail for 
immunoprecipitation and anti-pERM for immunoblotting, all the pERM was found in the 
not-bound fraction and none in the eluted fraction (Figure 36A).  Re-probing the same 
blot with anti-CD44-cytotail-HRP antibody confirmed that all CD44 was successfully 
immunoprecipitated in these samples (Figure 36B).   
 
 The Duterme et al., study also suggested that disruption or removal of HA leads 
to CD44 dissociation from the cytoskeleton through ERM (Duterme et al., 2009).  
Therefore we next compared parental RCS cells treated with testicular or Streptomyces 
hyaluronidase (to remove HA), to non-treated RCS cells.    Once again, using anti-
CD44-cytotail for immunoprecipitation and anti-pERM for immunoblotting, all the pERM 
was detected in the not-bound fraction (Figure 37A).    Re-probing with anti-CD44- 
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Figure 35: Co-immunoprecipitation of CD44 and pERM in RCS cells.  RCS cells 
were either transiently transfected with the non-relevant peptide or with CD44-ICD, or 
treated with IL-1. A. Cell lysates were immunoprecipitated with CD44-cytotail antibody 
and western blots probed with HRP-conjugated pERM antibody. All pERM was detected 
in the not-bound fraction.  B. Re-probing of the same blots using HRP-conjugated anti-
CD44 cytotail antibody confirmed that the majority of the CD44-FL was recovered in the 
eluted fraction. 
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Figure 36:  Co-immunoprecipitation of CD44 and pERM in BAC and RCS cells.  A. 
Cell lysates of BAC and RCS cells were immunoprecipitated with CD44-cytotail 
antibody and western blots were probed with an HRP-conjugated pERM antibody (top 
panel).  In addition, lysates derived from direct extraction of BAC or RCS cells were also 
examined.   All pERM was detected in the not-bound fraction for both cell lines.  B. Blot 
was re-probed with HRP-conjugated CD44-cytotail antibody, and most of the CD44-FL 
was detected in the eluted fraction (CD44-FL displays a different molecular mass in 
BAC compared to RCS possibly due to post-translational glycosylation). 
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Figure 37:  Co-immunoprecipitation of CD44 and pERM in RCS treated with 
HA’ase.  Cell lysates of RCS cells were prepared from untreated (control) RCS cells or 
RCS cells treated with testicular or Streptomyces HA’ase.  A. The lysates were 
immunoprecipitated with CD44-cytotail antibody and the western blot probed with a 
HRP-conjugated pERM antibody. All pERM was detected in the not-bound fraction for 
both cell lines and for all three conditions.  B. The blot was re-probed with HRP-
conjugated CD44-cytotail antibody, and most of the CD44-FL was detected in the eluted 
fraction (CD44-FL have different molecular mass in BAC and RCS likely due to post-
translational glycosylation). 
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cytotail-HRP antibody confirmed that CD44 was successfully immunoprecipitated 
(eluted fraction) (Figure 37B). 
 
 Numerous reports have noted that the interaction between CD44 and ERM is 
weak, especially in, in vitro assays.   Therefore, we examined the effects of detergent 
conditions on co-immunoprecipitations of CD44 and ERM in chondrocytes.  In this study 
lysates were made from monolayers of BACs and RCS cells.   Separate RCS cultures 
were extracted using a lysis buffer containing 50 mM Tris-HCl, 150 mM NaCl and, 5 mM 
EDTA and varying concentrations of NP-40 (0.1%, 0.25% and 0.5%).   Again, anti-
CD44-cytotail was used for immunoprecipitation and anti-pERM for immunoblotting.     
However, the results were similar to previous attempts to co-immunoprecipitate CD44 
and pERM, that is, all of the pERM was recovered in the not-bound fraction (Figure 
38A).    In another series of experiments with BACs, Triton X-100 and CHAPS at 
different concentrations (Figure 38C) were tested in comparison with 1% NP-40.  Under 
all these conditions, all pERM was detected in the non-bound fraction (Figure 38B). 
 
 These data would suggest that CD44 does not directly interact to pERM in 
chondrocytes.   To determine whether indirect interactions occur, the effect of CD44-
ICD over-expression on overall ERM phosphorylation was examined.   In this series of 
experiments, parental RCS cells were compared to RCS-CD44-ICD stable as well as 
CD44-ICD transient transfectants.   Western blots of total cell lysates demonstrated that 
ERM phosphorylation was lower in CD44-ICD over-expressing transfectants (Figure 
39).  These results suggest that CD44-ICD does affect ERM phosphorylation even  
  123 
 
   
 
 
 
Figure 38:  Co-immunoprecipitation of CD44 and pERM in BACs and RCS cells 
using different cell lysis detergents. Cell lysates were prepared from high density 
cultures of RCS cells (panel A) or BACs (panel B) using a select series of detergent 
conditions (panel C).  Cell lysates were immunoprecipitated with CD44-cytotail antibody 
and western blots probed with an HRP-conjugated pERM antibody.  Under all detergent 
conditions, all pERM was detected in the non-bound fraction only. No pERM was 
detected in the eluted fraction. 
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Figure 39:  Effect of over-expression of CD44-ICD on phosphorylation of ERM 
proteins in RCS cells.   RCS cells were transiently transfected with CD44-ICD, non-
relevant peptide plasmid, or plasmids expressing CD44-ICD or CD44-ICD-EGFP.   A 
and C. Lysates from these cells were directly extracted and analyzed by western 
blotting using an HRP-conjugated pERM antibody.  RCS cells transfected with the 
control non-relevant peptide, exhibited higher ERM phosphorylation compared to the 
two CD44-ICD transfectants suggesting that CD44-ICD does affect ERM 
phosphorylation.  B. Lysates were also obtained from control parental RCS cells and 
CD44-ICD stable transfectants.  Western blot analysis of these lysates also 
demonstrated a reduction in ERM phosphorylation in CD44-ICD over-expressing RCS 
cells as compared to control RCS cells.  All blots were re-probed using an anti-β-actin 
antibody. 
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though we cannot detect direct interaction between CD44 and pERM.  There remained 
the possibility that, in cartilage and chondrocytes, instead of CD44-FL binding to pERM, 
CD44 binds to non- phosphorylated ERM. 
  
To determine whether CD44-FL in chondrocytes binds to non-phosphorylated 
ERM, a series of co-immunoprecipitation experiments were performed using anti-CD44-
cytotail for immunoprecipitation and anti-total ERM for immunoblotting.  We first treated 
both parental RCS and RCS-CD44-ICD stable transfectants with or without 
Streptomyces hyaluronidase and then immunoprecipitated the cell lysates with anti-
CD44-cytotail antibody and immunobloted with anti-ERM antibody (HRP-conjugated). 
Similar to previous results with pERM, all ERM came down in the not-bound fraction 
and none was in the eluted fraction (Figure 40A).  Re-probing the blot with an HRP-
conjugated CD44-cytotail antibody, detected all CD44-FL in the eluted fraction (Figure 
40B).  As a control, beads were incubated with CD44-CD44-cytotail antibody but no 
lysate was added to the CD44-cytotail-beads complex.  If any bands were detected in 
the eluted fraction, then they were considered as non-specific. 
 
 In addition, RCS cells were lysed with four different detergents (D, E, F and G 
from figure 41B), immunoprecipitated with CD44-cytotail antibody and then 
immunoblotted with HRP-conjugated ERM antibody. Once again, no ERM was detected 
in the eluted portion (Figure 41A). 
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Figure 40:  Co-immunoprecipitation of CD44 and total ERM in parental RCS and 
RCS-CD44-ICD stable transfectants treated with HA’ase.  RCS parental and RCS-
CD44-ICD stable transfectant cells were treated with or without testicular HA’ase. The 
control bead column represents non-specific bands.  A. Cell lysates were 
immunoprecipitated with CD44-cytotail antibody and western blots probed with HRP-
conjugated total ERM antibody.  All ERM was detected in the not-bound fraction for both 
cell lines with or without HA’ase treatment.   B. Blot was re-probed with HRP-conjugated 
CD44-cytotail antibody, and most of the CD44-FL was detected in the eluted fraction.   
As a control, Dynabeads were incubated with the anti-CD44-cytotail antibody but 
without addition of a cell lysate.  Any bands present in the control beads fraction are 
considered non-specific possibly due to breakdown of the beads.   No nonspecific 
bands were detected using then anti-ERM antibody but, 25, 55 and 150 kD nonspecific 
bands were detected using HRP-CD44 cytotail antibody. 
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Figure 41:  Co-immunoprecipitation of CD44 and ERM in RCS using different cell 
lysis detergents.  A. RCS cells were lysed using four different select detergent 
conditions (D, E, F and G from panel B), immunoprecipitated with CD44-cytotail and 
western blots probed with an HRP-conjugated total ERM antibody.  All total ERM was 
detected in the not-bound fraction for all four different cell lysis detergent conditions.   
No ERM proteins were detected in the eluted fraction.  Re-probing of blots with HRP-
conjugated CD44-cytotail antibody detected all CD44-FL in the eluted portion (not 
shown).   Dynabeads incubated with the anti-CD44-cytotail antibody but without addition 
of a cell lysate exhibited a single nonspecific band detected using the anti-ERM 
antibody.  Control beads column represents non-specific bands. 
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On our last attempt to detect CD44/ERM or pERM interactions, dBACs were lysed and 
immunoprecipitated with CD44-cytotail antibody.  Lysates were immunobloted with 
either ERM or pERM-HRP conjugated antibodies, and in either case no ERM or pERM 
was detected in the eluted portion (Figure 42). 
 
At this point, we were unable to detect direct binding between CD44 and ERM or 
pERM.   Nonetheless over-expression of CD44-ICD resulted in a down-regulation of 
ERM phosphorylation.    The interaction between CD44-FL and pERM may be too weak 
to detect under immunoprecipitation conditions or a different actin adaptor protein is 
utilized in chondrocytes.  Our next attempt was to determine whether CD44 links to the 
cytoskeleton via members of the Ankyrin adapter family. 
 
2.2.3. CD44/Ankyrin interactions 
 Previous studies of demonstrated that in some cells including ovarian cancer cell 
line SKOV3, CD44 links to the underlying actin cytoskeleton by interactions with ankyrin 
(Lokeshwar et al., 1994; Singleton and Bourguignon, 2004).  Whether ankyrin interacts 
with CD44 in chondrocytes is unknown.  Which member of the ankyrin family (ANK1, 
ANK2 and ANK3) interacts with CD44 in chondrocytes or, whether usage of a particular 
ankyrin with CD44 is tissue dependent, is also unknown.   
 
 In our first study, cell lysates were prepared from parental RCS and SKOV3 cells 
and were immunoprecipitated with anti-CD44-cytotail antibody to pull down all CD44, 
and the western blot was probed with an HRP-conjugated ankyrin-3 antibody.  Several 
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Figure 42: Co-immunoprecipitation of CD44 and total ERM and pERM in dBACs.  
Cell lysates were prepared from confluent cultures of dBAC, immuno-precipitated with 
CD44-cytotail antibody, and then probed with HRP-conjugated total ERM antibody (left 
panel) or HRP-conjugated pERM antibody (middle panel).  The pERM blot was then re-
probed with HRP-conjugated CD44-cytotail antibody (right panel).   In addition, lysates 
derived from direct extraction of dBACs were also examined.   All ERM and pERM 
proteins were detected in the not-bound fraction.   CD44-FL (upper box in right panel) 
was detected in the eluted fraction.  Interestingly, protein bands equivalent in size to a 
CD44-ICD (lower box in right panel) were detected in the not-bound fraction and in the 
total cell lysate. 
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bands were detected in the eluted fraction and others in the not-bound fraction, likely as 
a result of different isoforms of Ankyrin-3 present in both cells lines (Figure 43A top 
panel). In addition, SKOV3 lysates were probed for pERM and ERM, but neither was 
detected in the eluted fraction (Figure 43B).  Re-probing with HRP-conjugated CD44-
cytotail antibody detected most of CD44-FL in the eluted fraction (Figure 43A bottom 
panel). 
 
In another set of experiments, cell lysates were prepared from parental RCS and 
stable RCS-CD44-ICD transfectants.   The anti-CD44-cytotail antibody was used to pull 
down all CD44, and the western blots were probed with a HRP-conjugated anti-Ankyrin-
3 antibody.   Two bands of ~65 kD and ~130 kD were highly expressed in lysates from 
both the parental RCS cell line and RCS-CD44-ICD stable transfectants (Figure 44A).  
These two bands likely represent isoforms of Ankyrin-3 reported at 50-190 kD (Santa 
Cruz Biotechnology product sheet).   More importantly, in parental RCS, the 65 and 130 
kD bands were present in both the lysates before immunoprecipitation and the eluted 
fractions following immunoprecipitation of CD44. However, in the RCS-CD44-ICD stable 
transfectants, although both 65 and 130 kD bands were present in the lysates prior to 
immunoprecipitation, only the high molecular mass band (~130 kD) was detected in the 
eluted fraction following immunoprecipitation of CD44.   All of the low molecular weight, 
65 kD band was detected in the not-bound fraction (Figure 44A).  These results were 
replicated three times. 
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Figure 43: Co-immunoprecipitation of CD44 and cytoskeletal adaptor proteins in 
SKOV3 and RCS cells.  A. Cell lysates were prepared from SKOV3 and parental, 
control RCS cells.  The lysates were immunoprecipitated with CD44-cytotail antibody, 
and the western blots probed with HRP-conjugated ankyrin-3 antibody (top panel).  As 
seen in the red box area, many isoforms of ankyrin-3 were detected in the eluted 
fraction, as well as the not-bound fraction in lysates from both cell types.  Re-probing of 
blots with HRP-conjugated CD44-cytotail antibody (lower panel) detected CD44-FL 
predominately present in the eluted portion (red box area) in both cell types.  
Dynabeads incubated with the anti-CD44-cytotail antibody but without addition of a cell 
lysate exhibited a single 25 kD nonspecific band detected using the anti-ankyrin-3 
antibody and two nonspecific bands, ~25 and 60 kD using the anti-CD44 cytotail 
antibody. B. Western blots of SKOV3 immunoprecipitates with CD44-cytotail antibody in 
panel A were re-probed with HRP-conjugated pERM and anti-total ERM antibodies, and 
in both cases ERM and pERM were detected in the not-bound fraction.   Control eluted 
bands represent non-specific bands. 
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Figure 44: Co-immunoprecipitation of CD44 and Ankyrin-3 in RCS and RCS-CD44-
ICD stable transfectant cell lines.  A. Cell lysates of parental RCS and RCS-CD44-
ICD stable transfectants were immunoprecipitated with CD44-cytotail antibody and 
probed with an HRP-conjugated ankyrin-3 antibody.   Two ankyrin isoforms (65 kD and 
130 kD) were detected in the cell lysate of both RCS lines however, the 130 kD was the 
predominate isoform in the parental cells and the 65 kD isoform in the CD44-ICD stable 
transfectants.   Both isoforms were also detected in the eluted fraction of parental RCS 
cell lysates, however, the 130 kD isoform was predominate.   In RCS-CD44-ICD 
transfectants, only the high molecular mass, 130 kD isoform was detected in the eluted 
portion, and all of the lower molecular mass (65 kD) isoform was detected in the not-
bound fraction, suggesting that CD44-ICD over-expression directly affects CD44 
interactions with this ankyrin isoform.   B. Re-probing of blots with HRP-conjugated 
CD44-cytotail antibody detected CD44-FL predominately present in the eluted fraction 
of both RCS and RCS-CD44-ICD.   Additionally, the CD44-ICD, expressed in the stable 
RCS-CD44-ICD transfectants, was also recovered in the eluted fraction.  Dynabeads 
incubated with the anti-CD44-cytotail antibody but without addition of a cell lysate 
exhibited a single 25 kD non-specific band detected using the anti-ankyrin-3 antibody 
and two nonspecific bands, ~25 and 60 kD using the anti-CD44 cytotail antibody. 
 
A. 
B. 
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This same experiment was repeated with an ankyrin-1 antibody.  Many bands were 
detected in both RCS and RCS-CD44-ICD cell lysates, but none of the isoforms were 
detected in the eluted fraction of either cell line after immunoprecipitation with CD44-
cytotail antibody (Figure 45). 
  
These data suggest that CD44 binds to the actin cytoskeleton via two isoforms of 
ankyrin-3 in chondrocytes, and over-expression of CD44-ICD affects direct binding of 
CD44-FL with the lower molecular weight isoform of ankyrin-3.    These data might 
explain why endogenous CD44-FL can be extracted easily in RCS-CD44-ICD stable 
and transient transfectants when compared to parental cell line. 
 
2.2.4. Effect of CD44-ICD on CD44-FL phosphorylation (immunoprecipitation study). 
In resting cells, the majority of CD44 is phosphorylated at Ser325 (Peck and 
Isacke, 1998) and phosphorylation of Ser291 is required to dephosphorylate Ser325 to 
control and modulate receptor function (Legg et al., 2002).  However, it is difficult to 
study specific CD44 phosphorylation due to lack of commercial antibodies specific to 
CD44 phosphorylation sites. 
 
In order to determine whether CD44-ICD has an effect on endogenous CD44-FL 
phosphorylation, cell lysates were immunoprecipitated with CD44-cytotail antibody and 
then probed with a general phosphor-serine antibody.  The phosphorylation of CD44 
appears to decrease in stable RCS-CD44-ICD transfectants (Figure 46A), suggesting  
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Figure 45: Co-immunoprecipitation of CD44 and Ankyrin-1 in RCS and RCS-CD44-
ICD stable transfectant cell lines.  A. Cell lysates of parental RCS and RCS-CD44-
ICD stable transfectants were immunoprecipitated with CD44-cytotail antibody and 
probed with an HRP-conjugated ankyrin-1 antibody.   Several ankyrin isoforms were 
detected in the direct cell lysates and not-bound fractions of both RCS lines, and no 
bands were detected in the eluted fraction. No ankyrin bands were detected in the 
eluted fraction.  B. Re-probing of blot with HRP-conjugated CD44-cytotail antibody 
detected CD44-FL predominately present in the eluted fraction of both RCS and RCS-
CD44-ICD.   Additionally, the CD44-ICD, expressed in the stable RCS-CD44-ICD 
transfectants, was also recovered in the eluted fraction. 
 
 
 
A. 
B. 
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Figure 46: Changes in serine phosphorylation of CD44-FL in RCS and RCS-CD44-
ICD stable transfectant cell lines.  A. Cell lysates of parental RCS and RCS-CD44-
ICD stable transfectants were immunoprecipitated with CD44-cytotail antibody and 
western blots probed with an anti-phospho-serine antibody.  In addition, lysates derived 
from direct extraction of the two RCS lines were also examined.   In parental RCS cells, 
a prominent band possibly indicative of phospho-CD44-FL was detected in the eluted 
fraction.  The same band was also present in the total cell lysates of both RCS lines.   
However, in the eluted fraction of RCS-CD44-ICD stable transfectants, the expression 
of this band was down-regulated.  B. Re-probing of blots with HRP-conjugated CD44-
cytotail antibody detected CD44-FL predominately present in the eluted fraction of both 
RCS and RCS-CD44-ICD.   Additionally, the CD44-ICD, expressed in the stable RCS-
CD44-ICD transfectants, was also recovered in the eluted fraction.  Dynabeads 
incubated with the anti-CD44-cytotail antibody but without addition of a cell lysate 
exhibited ~25 and 60 kD nonspecific bands using the anti-phosphoserine and anti-CD44 
cytotail antibodies. 
 
A. 
B. 
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that CD44-ICD may downregulate endogenous CD44-FL phosphorylation.  When the 
blot was re-probed with an HRP-conjugated CD44-cytotail, most of the CD44-FL and all 
of the CD44-ICD were detected in the eluted fraction (Figure 46B). 
 
2.2.5. Generation of point mutations to block the effect of rhCD44-ICD on CD44-FL. 
 Two mutated CD44-ICD constructs were developed to try to block the effects of 
CD44-ICD on endogenous CD44-FL function using the GeneTailor™ Site Directed 
Mutagenesis System from Invitrogen.  The first point mutation was targeted to three 
positively charged residues of the ERM binding domain, located just distal to the plasma 
membrane.  According to Yonemura and colleagues, mutating K298K299K300 to 
Q298I299N300 resulted in no CD44-ERM binding (Yonemura et al., 1998). Therefore, our 
mutation strategy was to convert the positively charged KKK residues to QIN, as 
suggested by the previous study.  
  
 The next mutation was targeted to the ankyrin binding domain.  It was more 
challenging to decide which amino acids were crucial for CD44 binding to ankyrin, since 
to our knowledge the only studies addressing CD44 binding to ankyrin include truncated 
versions of the CD44 sequence rather than point mutations.  Our strategy was to target 
plausible residues within the putative ankyrin binding domain of CD44, similar to the 
approach we used with ERM mutation.  Given that CD44 binding to ERM seemed to 
rely on a cluster of three positively charged amino acids, we identified two basic 
residues in the ankyrin binding domain sequence of CD44 as a reasonable first step: 
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Arg313-Lys314.  Following a similar strategy used to introduce point mutations into the 
ERM binding domain, we mutated these two residues to Ile313-Asn314.   
 
 These two mutated peptides (CD44-ICD∆ERM and CD44-ICD∆Ank) were used 
in co-immunoprecipitation studies in an attempt to reverse any CD44-ICD effects on 
CD44-FL endogenous function.  Because we were unable to detect any direct 
interaction between CD44 and ERM, we did not expect to see any different result with 
CD44-ICD∆ERM.  However, we found that CD44-ICD affects CD44-FL binding to a ~65 
kD isoform of ankyrin3, and therefore expected to reverse these effects by transfecting 
RCS cells with CD44-ICD∆Ank.  Unfortunately, no changes were detected (results 
replicated twice) when compared to previous results. 
 
Definitive conclusions cannot be made for the lack of rescue of CD44-
ICD∆Ank as compared to the activity of wild-type CD44-ICD to block interactions 
of CD44-FL with ankyrin.     One possibility is that the amino acids that were 
chosen to alter within the ankyrin binding domain of the CD44-ICD were not 
crucial for CD44 binding to ankyrin, and therefore the results between the 
mutated peptide and CD44-ICD were similar.   A second possibility is that the 
point mutation protocol failed to change the desired amino acids within the 
ankyrin binding domain.    Subsequent DNA sequencing results confirmed that 
the Arg313-Lys314 to Ile313-Asn314 mutation was not present in the several of the 
bacterial colonies picked for expansion and plasmid purification.   It was later 
determined that the One Shot® MAX Efficiency® DH5á™-T1R competent cells, 
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used as part of the Invitrogen GeneTailor™ protocol were not effective in 
destroying the methylated-parental strands.   Thus, the resulting colonies likely 
contained a mixture of both parental and daughter strand clones.   To resolve this 
problem our laboratory subsequently included part of the protocol used in the 
QuikChange® Site-Directed Mutagenesis Kit from Stratagene.   In this protocol 
the CD44-ICD plasmid was methylated and re-amplified using the same strategy 
mutagenesis primers described previously in this study.   However, following the 
reaction, the Stratagene approach was carried out as the next step, using the 
restriction enzyme Dpn I to destroy all methylated parental DNA strands, instead 
of using the DH5á™-T1R bacteria.  Bacteria were grown in chemically competent 
TOP 10 cells, and colonies selected were purified and sequenced.   Sequencing 
results confirmed successful mutations, and these plasmids are now available for 
future studies. 
 
2.2.6. Co-immunoprecipitation studies to re-explore CD44-FL binding to Smad1. 
It still remains unclear whether cleaved CD44-ICD can interact with Smad1 and 
affect the natural signaling function of CD44-FL. To address this question, several co-
immunoprecipitation assays were developed to detect interactions between CD44-FL 
and CD44-ICD with Smad1. 
 
 First we treated parental and CD44-ICD stable transfectant RCS cells with or 
without BMP 7.  Cell lysates were immunoprecipitated with CD44-cytotail antibody and 
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probed with an HRP-conjugated Smad1 antibody. A 60 kD band was detected in all 
eluted fractions and did not seem to change between treatments or cell lines (Figure 
47).  It is still impossible to determine whether CD44-ICD is interacting with Smad1 
based on these results, due to the fact that the CD44-cytotail antibody pulls down both 
CD44-FL and CD44-ICD.   
 
 We then tried to immunoprecipitate the same lysates using a Smad1 antibody, 
and probed with an HRP-conjugated CD44-cytotail antibody to determine whether 
CD44-ICD could interact with Smad1.  A very small pool of CD44 was detected in the 
eluted fraction of both cell lysates when compared to the CD44 that did not bind (Figure 
48).  It appears that parental RCS had more CD44 binding to Smad1, but this could be 
due to unequal protein concentration between the two lysates (equal volume was 
loaded, and cell lysate fraction from the parental RCS contained more protein when 
compared to that of RCS-CD44-ICD).  Interestingly, a very faint band the size of CD44-
ICD is detected in the “not-bound” fraction of RCS-CD44-ICD stable transfectants, 
suggesting that CD44-ICD does not interact with Smad1. 
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Figure 47: Co-immunoprecipitation of CD44 and Smad1 in RCS and RCS-CD44-
ICD stable transfectant cell lines with or without BMP 7 treatment.  RCS and RCS-
CD44-ICD stable transfectants were either incubated with serum free media (control) or 
with BMP 7 for 1 hour.  Cells were immediately lysed, and cell lysates were 
immunoprecipitated with CD44-cytotail antibody and probed with an HRP-conjugated 
Smad1 antibody.  In all lysates, some Smad1 was detected in the eluted fraction (~60 
kD), but Smad1 interaction with CD44 did not seem to be affected by BMP 7 treatment 
or CD44-ICD over-expression. 
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Figure 48: Co-immunoprecipitation of CD44-FL in RCS and RCS-CD44-ICD stable 
transfectant cell lines.  RCS and RCS-CD44-ICD stable transfectants were lysed, 
immunoprecipitated with Smad1 antibody and probed with an HRP-conjugated CD44-
cytotail antibody.  Most of the CD44-FL was detected in the not-bound fraction; however 
a small pool was detected in the eluted fraction as well.  In parental RCS cells, a larger 
pool of CD44-FL was detected in the eluted fraction when compared to CD44-RCS-ICD 
stable transfectants.  In addition, all CD44-ICD from the RCS-CD44-ICD transfectants 
was detected in the not-bound fraction, suggesting that Smad1 does not bind to 
fragmented CD44-ICD.  The other bands in the eluted fraction are non-specific. 
 
 
 
 
 
 
 
 
 
   
CHAPTER 4: GENERAL DISCUSSION 
AND CONCLUSIONS 
 
 The main focus of this study was to investigate the effect of release of CD44-ICD 
fragments into the cytoplasm of cells, chondrocytes in particular.   Our hypothesis was 
that the free CD44-ICD would exhibit a competitive or “dominant-negative” effect on 
CD44-FL functions.   There are several reports in the literature that CD44 undergoes 
sequential proteolytic cleavage, releasing a soluble CD44 into the extracellular space as 
well as an intracellular fragment (CD44-ICD).    Proteolytic cleavage of CD44 is 
associated with pathological conditions such as cancer invasion and metastasis (Cichy 
and Pure, 2003; Guo et al., 1994; Lammich et al., 2002; Masson et al., 1999; Murakami 
et al., 2003; Okamoto et al., 1999a; Okamoto et al., 2001; Pelletier et al., 2006; Yamane 
et al., 1999) and rheumatoid arthritis (Haynes et al., 1991b).  Recently, our laboratory 
demonstrated that CD44 fragmentation was a prominent feature associated with 
osteoarthritic cartilage (Takahashi et al., 2010).  Although CD44 fragmentation is known 
to occur, little is known about the effects of this event on cell physiology. While CD44-
ICD may exert multiple of effects on cell behavior, this study focused on specific 
changes to cell functions dependent on CD44-FL. 
 
 The approach chosen to address more directly the effects of CD44-ICD release 
was to prepare a variety of eukaryotic expression plasmids containing the CD44-ICD 
domain.   These expression plasmids, when introduced into cells would provide for the 
select over-expression of an individual domain, the CD44-ICD.    
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 In the cloning of the CD44-ICD, several technical problems needed to be 
overcome to perform in-frame directional cloning, such as introducing the appropriate 
restriction sites in the primers, selecting the appropriate sequence to resemble the 
naturally-occurring cleaved CD44-ICD, introducing a start site in expression plasmids 
with a C-terminal epitope tag, selecting appropriate epitope tags and developing a 
control “untagged” plasmid.    
 
 After successfully generating and purifying a variety of CD44-ICD, CD44-FL and 
Smad1 plasmids (Figure 5), several cell lines, including chondrocytes, were transfected 
using the Amaxa nucleofection system.  Transfection efficiency was typically 
determined by immunofluorescent imaging 2 days after transfection, and experiments 
were conducted shortly after to verify successful transfection.      
 
 Although, useful data was obtained in some transient transfection experiments of 
primary chondrocytes culture, variability in transfection efficiency continued to limit the 
interpretation of our results.  In addition, after BAC transfection, cells had to be 
passaged at least once, which induced the chondrocytes to de-differentiate into more 
fibroblast-like cells (dBACs), therefore losing important characteristics of primary 
chondrocytes.    For example, as shown in Figure 49, the circumferential cortical 
organization of the actin cytoskeleton of primary chondrocytes takes on the appearance  
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Figure 49:  Rhodamine-phalloidin staining of primary BACs and dBACs. Primary 
cultures of BACs (A,B) and dBACs (C,D) were fixed, permeabilized and the actin 
cytoskeleton stained with rhodamine-phalloidin (red fluorescence).  The slides were 
then mounted with DAPI –containing mounting media (blue fluorescence).  As noted in 
A and B, the primary chondrocytes have a cortical actin cytoskeleton, characteristic of 
non-OA chondrocytes.  On the other hand, as BACs are passaged several times, they 
begin to lose their cortical morphology, and change into more fibroblast-looking cells 
with elongated processes (C and D).  This morphology has been reported in OA-
chondrocytes (Holloway et al., 2004). 
 
 
 
 
A. B. 
C. D. 
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of fibroblast stress-fiber organization in dBACs.   To address this problem, CD44-ICD-
expressing stable cell lines were generated (HEK-293 and RCS) using the Flp-In 
system from Invitrogen.  Once cells were successfully transfected, cells were kept in 
hygromycin-selective media to continue selection of CD44-ICD stable transfectants 
only.   The stable transfectant chondrocyte cell line, RCS, became an important tool in 
this study.    
 
 Once a viable method to study effects of CD44-ICD on CD44-FL function was 
obtained, several CD44-FL functions were examined in this study, including the effects 
on CD44-FL/Smad1 signaling pathway and the ability of CD44 to bind to HA and retain 
a pericellular coat.  If CD44-ICD does in fact have a dominant-negative effect on CD44-
FL functions, our next goal was to investigate the mechanisms involved in these 
competitive interactions. 
 
 First, we examined the possible effects of CD44-ICD on the CD44-FL/Smad1 
signaling pathway.  The putative Smad1 binding site on CD44 is located at the distal C-
terminal end of the CD44 intracellular domain (Peterson et al., 2004).    Since this 
binding site is present and intact within the CD44-ICD, we hypothesize that the CD44-
ICD could compete with CD44-FL for Smad1 binding.  Through this binding, CD44-ICD 
might sequester Smad1.  Because CD44-ICD is not anchored to the plasma membrane, 
it would not exhibit the same capacity to present Smad1 to the BMP receptor during the 
activation of the BMP 7 signaling pathway.   As a result, any Smad1 bound to CD44-
ICD will not be phosphorylated, and translocated to the nucleus.   Thus, we predicted 
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that overall Smad1 phosphorylation would be down-regulated in CD44-ICD transfected 
cell lines as compared to control or parental cells.  In addition, Smad1 would stay bound 
to CD44-ICD in a non-phosphorylated state and co-immunoprecipitate with CD44-ICD.  
 
 When Smad1 phosphorylation was investigated in RCS-CD44-ICD stable 
transfectants and parental cell lines, a down-regulation in Smad1 phosphorylation was 
observed in stable RCS-CD44-ICD cells.   In addition, when parental and CD44-ICD 
stable RCS transfectants were treated with or without BMP 7 for 1 hour, the RCS-CD44-
ICD cells did not respond to BMP 7 activation as strongly when compared to parental 
RCS. These results support part of our initial hypothesis that over-expression CD44-ICD 
would exert a negative effect on Smad1 phosphorylation. 
 
 Cell lysates of both parental RCS and RCS-CD44-ICD stable transfectants were 
immunoprecipitated using an anti-Smad1 antibody.  The blots were then probed with an 
HRP-conjugated anti-CD44-cytotail antibody to determine if any CD44-ICD could be 
detected.  Although CD44-FL was immunoprecipitated in parental RCS, a much smaller 
amount of CD44-FL was detected in anti-Smad1 immunoprecipitate of RCS-CD44-ICD 
stable transfectant lysates (Figure 48).  This could a result of unequal protein 
concentration between the two lysates, because equal volume is loaded in co-
immunoprecipitation assays as opposed to equal protein.  However, our attempts to co-
immunoprecipitate CD44-ICD with Smad1 were not successful (Figure 48).  One the 
one hand, these results suggest that CD44-ICD may interfere with CD44-FL binding to 
Smad1.   
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Unfortunately, no CD44-ICD was detected in the eluted fraction of RCS-CD44-
ICD stable transfectants.  Nonetheless, the downregulation of Smad1 phosphorylation 
and reduced immunoprecipitation of CD44-FL in CD44-ICD transfectants supports our 
hypothesis that CD44-ICD affects CD44/Smad1 signaling pathway in response to  
activation.   However, whether this is due to direct CD44-ICD / Smad1 sequestering or 
some other mechanism, remains to be determined. 
 
Attempts were also made in this study to follow Smad1 translocation to the 
nucleus using immunofluorescence microscopy, as a measure of Smad1 activation in 
response to activation.   Unfortunately, very limited translocation of the GFP/EGFP 
Smad1 fusion proteins was observed in parental C28/I2 cell line (Figure 21), and no 
translocation was observed in dBACs (Figure 22). 
 
 Our next goal was to investigate the effects of CD44-ICD on CD44-FL ability to 
retain a pericellular coat.  In chondrocytes, CD44 binds to HA, and therefore, CD44 is a 
critical component for the retention of the proteoglycan rich ECM (Knudson, 2003). 
Particle exclusion assays have been used in the past to visualize the pericellular matrix 
of individual chondrocytes.  We used this approach to investigate the effects of CD44-
ICD over-expression on the ability of CD44-FL to retain a pericellular coat in transient 
and stable CD44-ICD transfectants.   
 
 In initial experiments, we examined the effects of CD44-ICD on coat retention by 
using culture conditions that our laboratory had recently determined could induce 
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cleavage of endogenous CD44-FL (Takahashi et al., 2010).   Addition of agents such as 
IL-1β, PMA and HA oligosaccharides to normal BACs induced endogenous CD44-FL 
cleavage.   PMA has been used in several studies to initiate the sequential proteolytic 
cleavage of CD44 (Nagano et al., 2004).   Nagano and colleagues suggest that 
proteolytic cleavage is regulated by several signal pathways, including the extracellular 
influx of Ca2+, and activation of PKC, Ras oncoprotein and Rho family GTPases 
(Kawano et al., 2000; Okamoto et al., 1999b).  
 
 The consequence of adding these reagents to chondrocytes was examined on 
one of the prime functions of CD44-FL, its role in retaining a HA/proteoglycan-rich 
pericellular matrix.   Particle exclusion assay of BACs treated with IL-1β, PMA and HA 
oligosaccharides revealed a drastic reduction in the size of their pericellular coats.     
However, it is difficult to make unambiguous conclusions from these results because 
reagents like IL-1 and PMA are pleiotropic in their mechanism of action.  For example, 
IL-1 exerts both a catabolic effect (upregulation of MMPs and ADAMs) as well as an 
anti-anabolic effect (downregulates aggrecan expression) (D'Souza et al., 2000; 
Flannery et al., 1999; Little et al., 1999; Nishida et al., 2000). A more direct approach 
was needed to determine the cellular consequences of released intracellular CD44-ICD.   
 
 Our next approach was to investigate the effects on coat retention in 
chondrocytes expressing either transient or stable CD44-ICD.  Over-expression of 
CD44-ICD-EGFP in transiently transfected BAC (Figure 25) resulted in total loss of 
capacity to retain a pericellular coat as compared to non-transfected control cells.  
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Similar results were obtained with transient and stable CD44-ICD transfection of RCS 
cells (Figures 26-27).  One interpretation of the loss of coats on CD44-ICD 
transfectants, is that the CD44-ICD alters the capacity of the CD44-FL to bind or retain 
a level of HA necessary to maintain a pericellular matrix.   Other conclusions are also 
possible as the synthesis, retention and maintenance of pericellular matrices are 
dependent on multiple cellular events and pathways.  These events might somehow be 
affected by over-expression of the CD44-ICD.   Nonetheless, the overall effect on coats 
is consistent with our initial hypothesis that CD44-ICD has a negative effect on CD44-FL 
ability to retain a pericellular coat. 
 
       In addition, HABP staining of parental and stable CD44-ICD transfectants 
supported the results from the particle exclusion assay (Figure 29).  Parental RCS cells, 
that were predicted to have an intact CD44/HA interaction, displayed a continuous 
cortical ring of fluorescent HABP along the plasma membrane, suggesting that HA is 
bound to cell surface receptors throughout the cell.   However, stable RCS-CD44-ICD 
transfectants exhibited a disrupted pattern, rather than a total loss of HA.   This 
disrupted pattern is again not definitive, but consistent with the hypothesis that CD44-
ICD affects CD44/HA interactions.  It is also possible that the green fluorescence 
represents HA bound to the membrane HA synthase (HAS) rather than bound to CD44.    
Nonetheless, data on pericellular coat retention and HABP staining in chondrocytes 
over-expressing CD44-ICD supports our hypothesis that CD44-ICD may act by 
competing with functions of CD44-FL. 
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 Next we investigated whether CD44-FL binding to the cytoskeleton was affected 
by CD44-ICD over-expression.  Previous studies reported that the interaction between 
CD44-FL and the actin cytoskeleton is crucial for cartilage matrix retention.  Disruption 
of the actin network with reagents like cytochalasin D and latrunculin A resulted in 
easier extraction of CD44-FL, reduction in HA binding, pericellular matrix assembly and 
retention in chondrocytes (Nofal and Knudson, 2002). This is the only evidence to date 
showing that disrupting CD44-FL interactions with the cytoskeleton results in depletion 
of the pericellular matrix.  Our study intends to determine whether CD44-ICD could have 
a similar effect on CD44-FL function by competing with CD44-FL binding to the 
cytoskeleton.   
 
 Our first approach was to study CD44-FL extractability in parental and CD44-ICD 
transient and stable transfectants, using a differential extraction method similar to the 
one used by Nofal and Knudson.  In their study, they found that cytochalasin and 
latrunculin shifted CD44-FL from harsh to light extraction, suggesting that extraction 
with either harsh or with light detergents was dependent on CD44 attachment to the 
cytoskeleton (Nofal and Knudson, 2002).  First, we used a variety of conditions known 
to affect CD44/cytoskeleton interactions to test the differential extraction method.  For 
instance, it has been reported previously that disrupting CD44/HA interactions directly 
by adding competitors to the HA binding site such as HA oligos, results in disruption of 
CD44 with the cytoskeleton (Duterme et al., 2009).  When we treated BACs with HA 
oligos, most of the CD44-FL was easily extracted with the light detergent whereas the 
untreated cells required a harsh detergent to extract the majority of CD44-FL, 
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supporting previous studies.  Our goal in this study was to determine if the same effects 
can be replicated having an inside-out effect; that is, whether CD44-ICD over-
expression can have the same effect on CD44-FL extractability as HA oligos. 
 
 Results from several transient and stable CD44-ICD transfections in BACs and 
RCS cells were consistent with our hypothesis that CD44-ICD acts as a negative 
competitor to CD44-FL binding to the cytoskeleton inside the cell.  CD44-ICD 
transfectants had the majority of CD44-FL extracted under light conditions, compared to 
control cells, which required a harsh detergent to extract most of the CD44-FL.  
Although it could be argued that this method is not precise because it is dependent on 
the composition of the light detergent or lysis extractions conditions. Nevertheless, the 
method was very consistent throughout different experiments.  It was important, 
however, to treat control and experimental lysates equally (i.e. lyse with the same 
detergent aliquots at the same time) for each experiment, and to load equal volume 
rather than equal protein for gel electrophoresis analysis.  
 
 At this point, particle exclusion assay, HABP staining and differential extraction 
data provided enough evidence to support our initial hypothesis that CD44-ICD was 
acting as a negative competitor to CD44-FL function.  Our next goal was to explore the 
actual mechanism(s) involved in this competitive interaction.  Our experimental 
approach was to perform several co-immunoprecipitation studies to investigate 
cytoskeletal binding partners of CD44-FL, and determine whether CD44-ICD was 
directly competing with CD44-FL binding to the actin cytoskeleton. 
  152 
CD44, like other receptors, does not bind to the cytoskeleton directly but rather, 
via intermediary adaptor proteins.  Those most commonly studied in relationship to 
CD44 are members of the ERM family and the ankyrin family (Bourguignon et al., 1998; 
Duterme et al., 2009; Hirao et al., 1996; Legg and Isacke, 1998a; Mori et al., 2008; 
Singleton and Bourguignon, 2004; Tsukita and Yonemura, 1997). 
 
It remains unknown whether CD44 can interact with both ERM and ankyrin 
simultaneously forming a single complex, or if CD44/ERM and CD44/ankyrin represent 
two separate, mutually-exclusive complexes that are utilized in a tissue dependent 
manner.  Alternatively, perhaps CD44 has the ability to switch between ERM and 
ankyrin within a single cell type so as to confer a particular function.  There are several 
reports of CD44 binding to the cytoskeleton via ERM binding proteins (Duterme et al., 
2009; Hirao et al., 1996; Legg and Isacke, 1998; Mori et al., 2008; Tsukita and 
Yonemura, 1997), as well as others that demonstrate CD44 binding via ankyrin 
(Bourguignon et al., 1998; Singleton and Bourguignon, 2004).  However, to date, the 
cytoskeleton adaptor proteins that interact directly with CD44 in articular chondrocytes 
has not yet been identified. 
 
In this project, CD44/ERM interactions in chondrocytes were first investigated 
since a recent, contemporary report described these interactions in rat fibroblasts BB16 
cells (Duterme et al., 2009).  Moreover, this study demonstrated that ERM 
phosphorylation levels were lower in BB16 fibroblasts over-expressing hyaluronidase-2 
(Hyal2), as compared to parental cells.   Hyal2 interacts with CD44 disrupting the 
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receptor’s ability to bind to HA, which in turn, disrupts CD44/ERM binding and 
subsequent ERM phosphorylation.  Such an event could be denoted as an outside-in 
effect.   The effect of Hyal2 in this study is similar to changes in the differential 
extractability of CD44 that we observed in BACs treated with HA oligos.    Treatment of 
chondrocytes with HA oligos generates outside-in effects similar to Hyal2. For example, 
HA oligos treatment results in loss of chondrocyte pericellular matrices, and shifts the 
percentage of CD44 recovered under light detergent conditions.   A testable idea is that 
if Hyal2 alters CD44/ERM interactions in fibroblasts similar to the effects of HA oligos or 
purified hyaluronidase, either one of these treatments would similarly alter CD44/ERM 
interactions in chondrocytes.    
 
However, as illustrated in Figures 35 – 42, all of our attempts to co-immuno-
precipitate CD44 with ERM or pERM, under many different conditions, were 
unsuccessful.  A lysis buffer similar to that used by Duterme and colleagues to 
successfully co-immunoprecipitate CD44 and pERM in fibroblasts was tested but, no 
pERM was recovered in the eluted fraction (Figure 35-37, 42).   To more directly mimic 
their Hyal2 results, RCS cells were treated with our without testicular or Streptomyces 
HA’ase (Figure 37) yet we were still unable to co-immunoprecipitate pERM with CD44 
under these conditions.  The same negative results were obtained in experiments 
testing co-immunoprecipitation of either ERM or pERM with CD44 in both transient and 
stable CD44-ICD transfected chondrocyte cell lines using the same lysis buffer (Figure 
35, 37, 40).   Neither ERM nor pERM could be recovered in the immunoprecipitated 
CD44 fraction. 
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The study by Duterme and colleagues used a fibroblast cell line to demonstrate 
co-immunoprecipitation of CD44 with pERM (Duterme et al., 2009).    We attempted to 
mimic their results using dBACs.   As shown in Figure 49, dBACs exhibit several 
morphological features that are similar to fibroblasts including prominent actin stress 
fibers.   However once again, we were unable to detect a direct interaction between 
CD44 and either ERM or pERM in lysates of dBACs (Figure 42).   This suggests that 
that use of a specific cytoskeletal adaptor protein in association with CD44 is not 
dictated by the presence of a particular cytoskeletal architecture (cortical versus 
spread). 
 
To discount the possibility that the detergent concentration of the standard lysis 
buffer disrupted CD44/ERM or pERM interactions (Duterme et al. buffer = 10 mM Tris, 2 
mM EDTA, 1% Triton X-100, pH 7.5), a series of buffer conditions were tested to co-
immunoprecipitate CD44 and ERM.   All of the buffers were prepared in 150 mM NaCl, 
50 mM Tris-HCl and pH 7.5, using different detergents at varying concentrations 
(including triton X-100, NP-40 and CHAPS).  Under all extraction conditions, ERM or 
pERM did not co-immunoprecipitate with CD44 (Figure 38, 41). One conclusion from 
this study is that CD44 in chondrocytes or chondrocyte-derived cells, do not utilize or 
interact with ERM proteins as linkage adaptors to the actin cytoskeleton.   
 
Although direct interactions between CD44 and ERM proteins could not be 
demonstrated in this study, it remains possible that CD44 may affect ERM via other 
unknown secondary pathways.   In total cell extracts from CD44-ICD stable and 
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transient transfectants, ERM phosphorylation was consistently found to be 
downregulated as compared to non-transfected cells or cells transfected with the non-
relevant control peptide (Figure 39). Thus, a possibility remains that CD44-ICD over-
expression does affect the levels of pERM even though we were unable to detect direct 
interaction between CD44 and pERM.    
 
Other studies have suggested that CD44 links to the actin cytoskeleton via 
interactions with members of the ankyrin family of adaptor proteins (Bourguignon et al., 
1998; Lokeshwar et al., 1994; Singleton and Bourguignon, 2004; Zhu and Bourguignon, 
2000). Moreover, some of these reports have demonstrated that the binding affinity 
between CD44 and ankyrin is much higher than that of CD44 and ERM (Lokeshwar et 
al., 1994; Tsukita and Yonemura, 1997).  In addition, it has also been reported that 
CD44/ERM interactions cannot be detected in vitro or in vivo under normal physiological 
conditions.   To detect any CD44/ERM interactions, it is necessary to activate the Rho 
or protein kinase C pathways, which appears to be a requirement to induce binding 
(Hirao et al., 1996; Matsui et al., 1998). 
 
The ankyrin family consists of three different genes (ANK1, ANK2, ANK3) with 
each gene producing different isoforms through alternative splicing.    It is not clear 
whether all three ankyrin gene products can interact with CD44, or whether the 
particular ANK utilized is tissue dependent.   Several of the previous studies that 
document CD44/ankyrin interactions focused primarily on interactions of CD44 with the 
conserved Ankyrin Repeat Domain (ARD) present in all ankyrins.   Once again, there 
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are no reports of which ankyrin family members are expressed in chondrocytes, no 
reports that CD44 binds to ankyrins and, no evidence concerning which ANK member 
or members participate in CD44 / actin interactions. 
 
 In this study, potential interactions between CD44 and ankyrin-1 (ANK1) in 
chondrocytes were used as a starting point.   Zhu and Bourguignon had documented 
that CD44 and ANK1 co-immunoprecipitated with CD44 in SKOV3 human ovarian 
carcinoma cells (Zhu and Bourguignon, 2000).  Cell lysates of parental RCS and stable 
RCS-CD44-ICD transfectants were immunoprecipitated with CD44-cytotail antibody and 
then probed with an HRP-conjugated Ankyrin-1 antibody.  Although several bands were 
detected on the total cell lysates (possibly representing different Ankyrin isoforms), none 
of these isoforms were detected in the eluted fraction (Figure 45).    
 
 Our focus moved on to another ankyrin family member, Ankyrin-3 (ANK3).  ANK3 
had been previously found to be highly expressed in many tissues (Peters et al., 1995), 
but cartilage has not yet been specifically analyzed. Again, cell lysates of parental RCS 
and stable RCS-CD44-ICD transfectants as well as SKOV-3 cells, were 
immunoprecipitated with CD44-cytotail antibody and then analyzed with an HRP-
conjugated anti-ANK3 antibody.   In these experiments several ANK3-positive bands 
were detected in both the eluted and not-bound fractions, and these bands were similar 
in RCS and SKOV-3 cell lysates (Figure 43).   However, two bands were highly 
expressed in the RCS cell line (Figure 44), likely representing two different isoforms of 
Ankyrin-3 (~130 kD and ~65 kD).  In parental RCS cells, both bands were present in 
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total cell lysates and the eluted fractions, along with some in the not-bound fraction.  
This suggested that endogenous CD44-FL binds to both ANK3 isoforms.  However, in 
the RCS-CD44-ICD stable transfectants, only the high molecular mass band (130 kD) 
was detected in the eluted fraction, while all of the low molecular weight ANK3 isoform 
(65 kD) was recovered in the not-bound fraction.  These results were replicated three 
times.  These data suggest that over-expression of CD44-ICD does affect the binding of 
CD44-FL with the lower molecular weight, 65 kD isoform of ankyrin-3.      
 
Taken together, this study is the first to investigate the effects of having 
cytoplasmic CD44-ICD fragments on CD44-FL function in chondrocytes.  We have 
proposed that release of the CD44-ICD into the cytoplasm of chondrocytes would exert 
a competitive or dominant-negative effect on the CD44-FL functions.   This study has 
provided support for this hypothesis.    The rationale for suggesting a dominant-negative 
effect of the CD44-ICD is that there remains sufficient CD44-FL to bind HA when CD44-
ICD is over-expressed.    There is little change in the overall content of CD44-FL.    
Nonetheless, the CD44-FL does not support proper pericellular coat or HA retention, the 
CD44-FL is not strongly-anchored to the cells and does not continue to bind 65 kD 
ANK3.  This model is summarized in Figure 50. 
 
Our study demonstrated that the expression of CD44-ICD prevents the formation 
and retention of a pericellular matrix.   Loss of pericellular matrices such as the 
exposure of chondrocytes to HA oligosaccharides (Knudson et al., 2000; Ohno et al., 
2006; Schmitz et al., 2010) hyaluronidase (Ohno-Nakahara et al., 2006) or CD44 
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antisense oligonucleotides (Chow et al., 1998) results in stimulation of catabolic activity 
in chondrocytes and chondrolysis in cartilage tissue.   Loss of pericellular matrices due 
to exposure of chondrocytes to HA oligosaccharides also results in the proteolytic 
cleavage of CD44 and the generation of CD44-ICD (Takahashi et al., 2010).    As such, 
these events could contribute to a continued, downward spiral that perpetuates 
degradation and limits repair of articular cartilage.    An initial signal or trauma could 
result an initial disruption of pericellular matrix in cartilage, triggering enhanced 
production of proteases and, as a consequence, CD44-ICD formation.   Our laboratory 
recently reported an increase of CD44-ICD fragments in OA chondrocytes when 
compared to non-OA chondrocytes (Takahashi et al., 2010).  The release of CD44-ICD, 
in turn, would limit matrix repair and retention of the pericellular matrix.   A delay in 
reforming a pericellular matrix would induce further protease synthesis, thus 
perpetuating matrix loss.   Osteoarthritis is often considered a result of attempted-but-
ultimately failed repair.   As such, CD44-ICD formation could represent a contributing 
factor in the failed repair, perpetuating a downward spiral that results in progressive 
osteoarthritis.   Thus, this study provides a better understanding on what may occur 
during early stages of cartilage degradation leading to osteoarthritis.     
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Figure 50: CD44-ICD fragments compete with CD44-FL binding to the 
cytoskeleton via ankyrin-3 in chondrocytes. A. Under normal conditions, CD44-FL 
binds to the actin cytoskeleton inside the cell via ankyrin-3, allowing proper binding to 
HA on the outside.  B. When CD44-ICD fragments are produced and concentrate inside 
of the cell, they compete with CD44-FL by binding to low molecular weight ankyrin-3, 
allowing dissociation of CD44 from the actin cytoskeleton and thus affecting CD44/HA 
binding on the outside.
A. 
B. 
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